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I .  ABSTRACT 
Peritoneal dialysis is a successful end stage renal disease therapy, although a dismal 
long-term outcome has been reported in some studies, suggesting loss of PD benefits in the 
long-term, with a slightly higher risk for overall mortality and cardiovascular death, compared 
with hemodialysis. The reasons associated with this are not fully understood, but several 
authors hypothesized an association with metabolic derangements, due to the potential 
systemic effects associated with the use of glucose (the main osmotic agent used in PD 
prescriptions), maximally expressed by patients who present a peritoneal membrane fast 
transport status. In order to improve knowledge in this field, we developed a series of cross 
sectional and prospective clinical researches, to investigate the systemic impact of intrinsic 
aspects of the peritoneal dialysis technique, such as peritoneal membrane transport status, 
peritoneal glucose absorption and peritoneal dialysis modality, on relevant clinical issues: 
residual renal function, phosphate removal, nutritional status, insulin resistance and 
cardiovascular events, in a population of incident and prevalent patients under peritoneal 
dialysis. The deleterious effects of intra-peritoneal glucose into the membrane level are well 
established, leading to peritoneal membrane structural alterations that will conduct to 
ultrafiltration failure. For that reason, this thesis focused also on the functional evaluation of 
the peritoneal membrane, establishing a new peritoneal equilibration test to evaluate 
simultaneously small solute transport and water transport pathways, and explores new 
peritoneal effluent biomarkers that could timely signalize peritoneal membrane dysfunction, 
even before clinically relevant ultrafiltration failure develops. 
We started to investigate the factors conditioning residual renal function (RRF) decline 
in 148 consecutive incident PD patients, treated in our Unit between January 2000 and June 
2007 (chapter V.I). Our clinical investigation has evidenced that patients on PD after renal 
transplantation experience similar short term RRF protection, without a shorter peritonitis-free 
survival, compared with patients starting PD as their first renal replacement therapy. We also 
concluded that diabetes was the only independent predictor of anuria, after PD start. 
In a second clinical investigation about peritoneal membrane phosphate transport 
(chapter V.II), we concluded that in hyperphosphatemic and or anuric patients, the decision 
on the optimal PD modality should also take into account peritoneal phosphate transport 
characteristics, beyond the traditional adequacy parameters (urea Kt/V and creatinine 
peritoneal clearance). Increasing dwell times or transfer to CAPD, could be effective strategies 
to improve phosphate handling in patients with inadequate phosphate control on APD, 
especially if they are slow phosphate transporters. 
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We also performed a cross sectional study in order to evaluate the nutritional status of 
57 PD patients in treatment in our Unit (chapter V.III), according to the most recent diagnostic 
criteria for nutritional assessment in chronic kidney disease patients. We have documented a 
high overweight and obesity prevalence, and a low incidence of protein-wasting. In a 
subsequent study, we have explored the associations between body composition, using a 
bioimpedance device (Body Composition Monitor), peritoneal membrane transport status, 
peritoneal glucose absorption and adipokines profile with cardiovascular events, in a group of 
66 PD patients, prospectively followed for 47 months (chapter V.IV.I). Our results clearly 
demonstrate that body mass index (BMI) underestimates the real prevalence of obesity, 
compared with body composition assessment using bioimpedance analysis, in PD patients. 
Nevertheless, we could not found any association between peritoneal glucose absorption and 
small solute transport status with obesity. However, according to our clinical investigation, 
cardiovascular events were associated with obesity. This study enabled us, additionally, to 
clarify that adipokines profile depends on patient´s body composition, as leptin/adiponectin 
ratio was predicted by relative fat mass and lean tissue index, independently of peritoneal 
glucose absorption. We have also concluded that a higher leptin/adiponectin ratio (LAR) was 
associated with new cardiovascular events, and can represent a new atherogenic index in 
patients under PD, without protein wasting.   
We also conducted a cross sectional study in order to assess insulin resistance 
prevalence and their determinants in a population non-diabetic patients, currently on treatment 
in our Unit (chapter V.IV.II). Our results show that obesity and adipokines profile play a major 
role in insulin resistance development in PD, independently of glucose absorption and small 
solute transport status. Given the already established association between insulin resistance, 
adipokines, and cardiovascular events (as our previous investigation demonstrates – chapter 
V.IV.I), efforts should be put in obesity prevention, correct diagnosis and management. 
Contemporary PD treatments minimize glucose exposition, and the lack of correlations 
between peritoneal glucose absorption, insulin resistance indices and body composition 
parameters, that we documented, puts on evidence that other presumably more powerful 
factors may contribute to the metabolic syndrome in PD patients. Finally, with this investigation, 
we also concluded that fast transporters, under updated PD prescriptions, can be adequately 
managed without higher risk of developing obesity or an insulin resistant state. 
Finally, since the peritoneum is a determining interface between the dialysis system 
and the systemic milieu, we focused on functional membrane evaluation, with a full 
characterization of both small-solute transport and water transport pathways across the 
membrane (chapter V.V.I). We have further explored new effluent biomarkers that could timely 
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signalize peritoneal membrane deterioration (chapter V.V.II). We have concluded that 
quantification of free water transport (FWT) is important for detecting causes of ultrafiltration 
failure (UFF), beyond an increase in effective capillary surface, and that such quantification is 
feasible during a 4-hour, 3.86% glucose PET evaluation, with a temporary drainage of the 
peritoneal cavity at 60 minutes (chapter V.V.I). In a subsequent study (chapter V.V.II), 68 PD 
patients were evaluated using the Two-In-One protocol, and hepatocyte growth factor (HGF) 
in the effluent was measured, in order to explore its association with water transport pathways 
and ultrafiltration failure profile. Since HGF is known to ameliorate peritoneal fibrosis in an ex-
vivo study, a clinical investigation like ours looks opportune. Our results demonstrate that 
dialysate HGF concentration is significantly higher among patients with UFF, especially if FWT 
is impaired, suggesting that it might be a useful marker of progressive peritoneal membrane 
dysfunction. 
 
KEY WORDS: adipokines, body composition, cardiovascular disease, fast transporters,  free 
water transport, hepatocyte growth factor, hyperphosphatemia, insulin resistance, nutrition 
status,  obesity, overweight, peritoneal dialysis, peritoneal equilibration test, peritoneal glucose 
absorption, peritoneal phosphate clearance, protein wasting, renal graft failure, residual renal 
function, ultrafiltration failure.  
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I .  RESUMO 
 A diálise peritoneal constitui uma eficaz terapêutica substitutiva da função renal, 
embora alguns estudos sugiram uma perda de vantagens da DP a longo prazo, com um maior 
risco de morte de causa cardiovascular associado a esta técnica, quando comparada com a 
hemodiálise. As razões associadas a estes resultados menos favoráveis não foram, até ao 
momento, completamente clarificadas. Contudo, vários autores colocam a hipótese de que o 
uso de glicose intraperitoneal (usada como agente osmótico na maioria das prescrições em 
diálise peritoneal) possa associar-se a resultados deletérios, a longo prazo, através dos seus 
potenciais efeitos sistémicos. Nesta linha conceptual, os doentes com perfil de transporte de 
membrana peritoneal rápido seriam os mais afetados. No sentido de amplificar o atual 
conhecimento científico nesta área, desenvolvemos uma série de estudos transversais e 
prospetivos envolvendo doentes incidentes e prevalentes na técnica, que nos permitiram 
investigar o impacto sistémico de aspetos intrínsecos à diálise peritoneal, tais como o tipo de 
transporte da membrana peritoneal, a absorção da glicose intraperitoneal e o tipo de 
modalidade de diálise peritoneal, em questões clínicas relevantes, nomeadamente: função 
renal residual, remoção peritoneal de fósforo, estado nutricional, insulinorresistência e eventos 
cardiovasculares. Os efeitos deletérios da glicose intraperitoneal ao nível da membrana 
peritoneal estão já bem documentados, originando com o tempo determinadas alterações 
estruturais na membrana conducentes à falência de ultrafiltração. Face ao exposto, a presente 
tese pretendeu estudar também a membrana peritoneal do ponto de vista funcional, 
estabelecendo um novo teste de equilíbrio peritoneal que permitisse avaliar, em simultâneo, 
o transporte de pequenos solutos e de água, explorando novos biomarcadores que 
permitissem sinalizar precocemente a disfunção da membrana peritoneal, antes mesmo do 
desenvolvimento de uma situação tardia de falência de ultrafiltração. 
 Começámos por investigar os fatores que condicionam a perda de função renal 
residual num grupo de 148 doentes consecutivos e incidentes, tratados na nossa Unidade 
entre janeiro de 2000 e junho de 2007 (capítulo V.I). A investigação clínica efetuada 
evidenciou que os doentes em diálise peritoneal após falência do enxerto renal apresentam, 
quando comparados com doentes que iniciaram diálise peritoneal como primeira técnica 
substitutiva da função renal, semelhante proteção da função renal residual, com tempo de 
sobrevida livre de peritonite similar. Concluímos ainda que a diabetes foi o único fator preditor 
independente de anúria após o início de diálise peritoneal. 
 Numa segunda investigação clínica acerca do transporte peritoneal de fósforo 
(capítulo V.II), concluímos que, nos doentes com hiperfosfatemia e ou anúria, a decisão 
quanto à modalidade terapêutica mais eficaz deve ter em consideração as características da 
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membrana quanto ao transporte de fósforo, para além dos tradicionais parâmetros de 
adequação em diálise (Kt/V ureia e clearance peritoneal de creatinina). Aumentar os tempos 
de permanência das trocas ou transferir o doente para uma modalidade de diálise peritoneal 
contínua de ambulatório, poderão ser estratégias eficazes no sentido de melhorar a remoção 
dialítica de fósforo em doentes no regime de diálise peritoneal automática que exibam um 
controlo do fósforo inadequado, especialmente se os mesmos apresentarem um estado de 
lento transporte da membrana peritoneal, no que ao fósforo diz respeito.   
 Efetuámos também um estudo transversal no sentido de avaliar o estado nutricional 
de 57 doentes em tratamento na nossa Unidade (capítulo V.III), de acordo com os mais 
recentes critérios de avaliação do estado nutricional na doença renal crónica. Documentámos 
uma elevada prevalência de excesso de peso e de obesidade e uma baixa incidência de 
desnutrição proteica nos doentes avaliados. Num estudo subsequente, explorámos as 
associações entre vários parâmetros de composição corporal avaliados por bioimpedância 
(Body Composition Monitor), estado de transporte da membrana peritoneal e perfil de 
adipocinas com os eventos cardiovasculares, numa população de 66 doentes em diálise 
peritoneal que foram prospetivamente estudados ao longo de um tempo médio de seguimento 
de 47 meses (capítulo V.IV.I). Os resultados obtidos demonstram que o índice de massa 
corporal subestima a real prevalência de obesidade nos doentes em diálise peritoneal, quando 
comparado com a avaliação da composição corporal efetuada por bioimpedância. Contudo, 
não encontrámos qualquer associação entre absorção de glicose intraperitoneal ou transporte 
peritoneal com obesidade. Todavia, de acordo com esta investigação clínica, existe uma 
associação entre obesidade no doente em diálise peritoneal e novos eventos 
cardiovasculares. Este estudo permitiu-nos ainda, adicionalmente, clarificar que o perfil de 
adipocinas, nos doentes em diálise peritoneal, é dependente da composição corporal, uma 
vez que a percentagem relativa de massa gorda e o índice de massa magra foram preditores 
do rácio leptina/adiponectina, independentemente da absorção intraperitoneal de glicose. 
Concluímos, por fim, que um rácio elevado de leptina/adiponectina se associa a novos 
eventos cardiovasculares, podendo representar um novo índice aterogénico na população de 
doentes em diálise peritoneal sem desnutrição proteica. 
 No sentido de avaliar a prevalência de insulinorresistência e de estabelecer os seus 
determinantes, efetuámos um estudo transversal que incluiu doentes não diabéticos em 
tratamento na nossa Unidade (capítulo V.IV.II). Os resultados obtidos evidenciam que a 
obesidade e o perfil de adipocinas desempenham um papel determinante no desenvolvimento 
de um estado de insulinorresistência nos doentes em diálise peritoneal, independentemente 
da absorção intraperitoneal de glicose e do estado de transporte da membrana peritoneal. 
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Dada a associação que previamente documentámos entre insulinorresistência, adipocinas, e 
novos eventos cardiovasculares (capítulo V.IV.I), esforços devem ser feitos no sentido de 
implementar medidas de prevenção da obesidade, mas também de otimizar o seu correto 
diagnóstico e sua gestão terapêutica. Os atuais regimes de prescrição terapêutica na diálise 
peritoneal minimizam a exposição a glicose, e, adicionalmente, a ausência de correlações 
encontradas entre a absorção de glicose intraperitoneal, os índices de insulinorresistência e 
os parâmetros de composição corporal, colocam em evidência que outros fatores, porventura 
mais determinantes, possam contribuir para o desenvolvimento de um síndrome metabólico 
nos doentes em diálise peritoneal. Por fim, a investigação clínica efetuada permitiu concluir 
que os doentes com perfil de rápido transporte de membrana peritoneal podem ser 
adequadamente tratados em diálise peritoneal, através de regimes de prescrição atuais e 
individualizados, sem que apresentem maior risco de desenvolver obesidade ou 
insulinorresistência. 
Por último, sendo o peritoneu uma interface determinante entre o sistema de dialise e 
o meio interno, efetuámos uma avaliação funcional da membrana peritoneal, caracterizando 
o transporte de pequenos solutos e da água (capítulo V.V.I). Explorámos novos 
biomarcadores no efluente peritoneal suscetíveis de sinalizar precocemente uma situação de 
disfunção da membrana peritoneal (capítulo V.V.II). Concluímos que a quantificação do 
transporte de água livre é importante para a deteção de outras causas de falência de 
ultrafiltração, para além de um aumento da superfície capilar efetiva, e que essa quantificação 
pode ser feita durante um teste de equilíbrio peritoneal de 4 horas, com 3.86% de glicose, e 
que envolve uma etapa adicional de drenagem temporária da cavidade peritoneal aos 60 
minutos (capítulo V.V.I). Num estudo posterior (capítulo V.V.II), 68 doentes em diálise 
peritoneal foram avaliados através do protocolo “Two-in-One”, tendo sido adicionalmente 
medido no efluente o “hepatocyte growth factor” (HGF), no sentido de explorar a sua 
associação com a disfunção da membrana peritoneal. Tendo sido já previamente 
documentado, num estudo ex-vivo, que o HGF pode condicionar uma melhoria do grau de 
fibrose peritoneal, uma investigação clínica como esta é oportuna. Os resultados que 
obtivemos evidenciam que a concentração de HGF no efluente peritoneal é significativamente 
maior nos doentes com falência de ultrafiltração de membrana, especialmente se o transporte 
de água livre estiver comprometido, o que sugere que possa ser um biomarcador útil de 
disfunção da membrana peritoneal. 
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PALAVRAS-CHAVE: absorção de glicose intraperitoneal, adipocinas, clearance peritoneal 
de fósforo, composição corporal, desnutrição proteica, doença cardiovascular, estado 
nutricional, excesso ponderal, falência de enxerto renal, falência de ultrafiltração, função renal 
residual, hepatocyte growth factor, hiperfosfatemia, insulinorresistência, obesidade, rápido 
transportador, transporte de água livre, teste de equilíbrio peritoneal.  
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I I .  INTRODUCTION 
1. Peritoneal Dialysis – a successful end stage renal disease therapy 
Peritoneal dialysis (PD) has been used as a successful end stage renal disease 
(ESRD) therapy over the last years, with significant differences in technique prevalence 
distribution all around the world (1). Current evidence shows that survival outcomes are 
now globally, at least, equivalent for both dialysis techniques (2-5), as PD results have 
improved during the past decade (3, 4). Cardiovascular disease is still the main cause of 
mortality in both hemodialysis and peritoneal dialysis patients (6). However, it seems that 
results are slightly different in terms of early versus long term survival between the two 
modalities. In fact, several studies have showed, in a consistent way, that peritoneal 
dialysis patients have a lower risk of death in the first years of ESRD (3, 7, 8), with the 
magnitude and length of time which this lower risk for death is evident depending on age, 
diabetes and the presence of associated comorbidities. The early survival benefit observed 
in peritoneal dialysis has been partially attributed to a better preservation of residual renal 
function by this technique compared to hemodialysis (9), that would offset the potentially 
deleterious systemic consequences of daily glucose loading. In fact, patients with residual 
renal function have lower degrees of inflammation and malnutrition, less hypertension with 
less cardiac hypertrophy, less anemia with less erythropoietin resistance, and a better 
phosphate control (10), all of which may explain the better overall and cardiovascular 
survival observed in the first years of peritoneal dialysis. As for long term survival 
comparisons between the two techniques, a recent study by Kumar and colleagues (8) as 
showed that, in an as-treated analysis, the 3-9 years survival was similar between the two 
modalities. However, others (11) have demonstrated that PD was associated with an 
increased risk for overall mortality and cardiovascular death, after two years of treatment. 
The reason for this dismal outcome after the first years of dialysis is uncertain. Although 
speculative, it is feared that with time, PD patients could be prone to suffer from protein 
wasting for one hand, and for the other, that peritoneal exposure to dextrose could lead to 
hyperglycemia, insulin resistance, dyslipidemia and metabolic syndrome (8, 11). In line 
with these hypotheses, the increased risk for cardiovascular death seen, with time on PD, 
could be a consequence of malnutrition-inflammation-atherosclerosis syndrome, or a 
consequence of metabolic syndrome and the systemic impact of peritoneal glucose 
exposure. In order to better understand the relation of cardiovascular risk with nutrition 
status in PD, contemporary studies about the impact of protein wasting and obesity in PD 
patient´s outcomes, with full body composition characterization, are needed. 
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2. Clinical outcomes in PD: the role of adequacy, small-solute transport and 
ultrafiltration on patient and technique survival 
An association between greater clearance of small molecular weight solutes and better 
clinical outcomes has been reported in a prospective cohort study (12). As residual renal 
function was not examined separately as a risk factor for clinical outcomes, renal and 
peritoneal clearances were assumed as comparable, and therefore additive. However, 
reanalysis of the CANUSA (13) data indicates that the contribution of residual renal function is 
even more important than peritoneal creatinine clearance in terms of patient survival, 
confirming previous observations from Maiorca et al. (14) and Diaz-Buxo et al. (15). This 
concept was additionally reinforced by the ADEMEX study (16), which showed that increasing 
further small solute clearances conferred no survival benefit in PD patients as a whole, or in 
the subgroup of anurics, and confirming that only residual renal function was predictive of 
outcome in these patients. It seems that the advantage conferred by preserved residual renal 
function (RRF) may be related to the volume of urine excreted and to the maintenance of an 
euvolemic state, as for each additional 250 mL of urine excreted per day, the relative risk of 
death was decreased by 36% (13). Better preservation of renal endocrine function and better 
clearance of middle and larger molecular weight uremic toxins are also plausible reasons for 
better outcomes in patients maintaining RRF, as clearances of middle molecules and protein-
bound solutes cannot be equalled by peritoneal dialysis (17). Residual renal function plays a 
central role in dialysis patients, whichever the modality, being linked with patient survival, but 
it has been focused more in PD. As a result, determining the factors that affect its loss has 
become an important issue in the care of patients under PD. Several factors have been 
associated with loss of RRF: larger body mass index, congestive heart failure, diabetes, 
hypotensive episodes, use of diuretics and peritonitis episodes (18-20). However, results are 
not consistent, and the investigations performed often exclude patients with a failed renal graft. 
There is also much debate about peritoneal membrane transport status and PD modality 
impacts on residual renal function (20), a clinically relevant aspect that deserves further 
clarification.  
In terms of adequacy, studies have simply focused on urea and creatinine clearances 
(12, 16) and the same is true about the most recent guidelines (21). However, theoretically, 
targets for others solutes removal by dialysis, as phosphate, should also be included, as we 
know that hyperphosphatemia is common in peritoneal dialysis patients, especially when 
residual renal function is lost (22), and it is a well-known factor for cardiovascular morbidity 
and mortality in these patients (23-25). Research into the relationship between phosphate 
clearance, membrane transport status and PD modality is needed, because optimization of 
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peritoneal phosphate clearance may be a reasonable goal for adequacy in the absence of 
compelling evidence for a link between urea clearance and outcome on PD (16).  
One of the first studies that explored the association between peritoneal membrane 
transport and technique and patient survival evidenced that fast transporters had a similar 2 
year survival probability compared with non-fast transporters (26). However, the 2 year 
probability of combined patient and technique survival was significantly lower in fast 
transporters. The authors hypothesized that fast transporters could be prone to develop 
malnutrition, fluid overload and insulin resistance with a more atherogenic lipid profile, that 
would translate into a decreased patient and technique survival (26). More recently (27, 28), 
the use of automated peritoneal dialysis was able to optimize volume control in fast 
transporters abolishing this previously reported worse outcome (29), but doubts still remain 
concerning metabolic derangements. In order to explore this relevant issue, studies that 
specifically address the impact of fast transport status on body composition changes and 
insulin resistance development, with time on PD, are lacking. Future studies about the impact 
of fast transport status on outcomes should also focus dialysis prescription in terms of 
peritoneal dialysis modality and dialysis solutions used, in order to assess if potential 
deleterious systemic consequences of membrane fast transport could be mitigated by an 
adequate PD prescription. 
The importance of ultrafiltration in PD patient´s outcomes was first evidenced in the 
EAPOS study (30). According to this prospective study, baseline predictors of poor survival in 
a group of 177 anuric patients under automatic peritoneal dialysis were age, nutritional status, 
diabetes and ultrafiltration (ultrafiltration < 750 mL/24h; P=0.047). These results stress the 
importance to monitor ultrafiltration profile changes, with time on PD, in order to timely adjust 
dialysis prescription.  
In summary, in order to improve both patient and technique survival, future 
investigations have first to clarify how particular aspects of therapy, such as peritoneal glucose 
absorption, membrane transport status and PD modality, impact systemically in these patients, 
in terms of preservation of residual renal function, maintenance of phosphate control, and 
development of protein wasting, obesity and insulin resistance. At the same time, as 
ultrafiltration is a major determinant of patient and technique survival, studies should also focus 
on membrane evaluation, with a full characterization of both small-solute transport and water 
transport pathways across the membrane, and exploring new biomarkers that could timely 
signalize peritoneal membrane deterioration, even before clinically relevant ultrafiltration 
failure develops. Investigation about the systemic impact of inner aspects of the technique, 
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and improving knowledge on functional evaluation of peritoneal membrane are, nowadays, the 
new challenges in peritoneal dialysis field. 
 
3. Controversies on the systemic impact of peritoneal glucose absorption and 
membrane fast transport status 
Glucose has been used over the past 3 decades as the main osmotic agent in 
peritoneal dialysis, allowing for sustained ultrafiltration, and enabling good results in terms of 
patient and technique survival. Approximately 75% of the dialysate glucose is absorbed (31, 
32) , and although there is a difference in the kinetics of glucose oxidation between 
intraperitoneal glucose and an equivalent oral dose, the cumulative glucose oxidation and 
glucose balance over a 6 hour study is similar for both routes of administration (33). Such 
findings raises the question about the potential role of glucose absorption in obesity and insulin 
resistance development in PD patients (34). In fact, several studies documented that, with time 
on PD, there is an increasing prevalence of obesity and overweight, but a direct association 
with peritoneal glucose absorption or fast transport status is not proven (35, 36).  
Insulin resistance and hyperinsulinemia are already present in early stages of chronic 
kidney disease (CKD) (37) and peritoneal dialysis seems to improve insulin sensitivity similarly 
to hemodialysis, at least for a short time frame (38). However, following glucose ingestion, 
peritoneal dialysis patients displayed an increase in the glycemic and insulinemic responses 
compared to healthy subjects, suggesting an insulin resistant state (31, 39). There is a 
pathophysiologic link between obesity and insulin resistance, as in obese patients the 
adipocytes will release substantial amounts of free fatty acids and adipocytokines, like tumour 
necrosis factor-alfa, interleukin-6 and leptin, that will promote insulin resistance trough different 
pathways (40, 41). Obesity, insulin resistance, dyslipidemia and hypertension are considered 
a cluster of risk factors for type 2 diabetes and cardiovascular disease in the general 
population, and define the metabolic syndrome (42-44). As compared with hemodialysis or 
pre-dialysis patients, uremic patients under PD seem to have a higher risk for metabolic 
syndrome (45, 46) because of increased risk of metabolic disturbances such as 
hyperglycemia, hyperinsulinemia and weight gain. However, results are not consensual about 
the predictive power of metabolic syndrome as a cluster of risk factors for cardiovascular or 
all-cause mortality in PD patients (47-50), and this lack of evidence in PD may be explained 
by several reasons. First, we have to consider that some of the risk factors in metabolic 
syndrome, as higher cholesterol levels and higher body mass index (BMI) are associated with 
a better nutrition status, and therefore are most likely paradoxically associated with better 
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clinical outcomes (51-54). Second, even the most recently proposed diagnostic criteria for 
metabolic syndrome in peritoneal dialysis patients (55) have important limitations in terms of 
obesity evaluation. The authors proposed measuring obesity in PD patients according to BMI, 
instead of using waist circumference, as it is proposed by the National Cholesterol Education 
Program Adult Treatment Panel III (42) and the International Diabetes Federation, for the 
general population (43). In fact, it must be considered that waist circumference may not reliably 
reflect abdominal visceral fat content in PD patients, due to the presence of a catheter, lax skin 
condition after repeated distention of the abdomen by peritoneal dialysis fluid, and by the 
potential interference of residual volume inside the abdomen cavity. However, we may also 
argue against the use of BMI to characterize obesity, since a recent study has demonstrated 
that, in general population, BMI is an inaccurate obesity classification method when compared 
with measurement of relative body fat by dual X-ray absorptiometry (56). As CKD patients can 
present simultaneous changes in nutritional status, body fat content and hydration status, BMI 
may have even lower sensitivity and specificity in obesity characterization in patients under 
dialysis. This was recently documented in a study reporting that a BMI < 30 Kg/m2 does not 
exclude the presence of obesity in a group of incident and prevalent patients under 
hemodialysis, evaluated by anthropometry (57). Similar studies in the peritoneal dialysis field 
are needed. The limitations in the diagnostic criteria, the lack of standardized definition and 
the bias imposed by the absence of body composition assessment, may explain the 
controversies about the systemic impacts of metabolic syndrome on PD patient outcomes. 
Although patients on PD are highly susceptible to the metabolic complications included in 
metabolic syndrome, there is no consensus about the clinical impact of these metabolic 
derangements when analysed both separately and as a whole (48-50). Therefore, rather than 
using a cluster of risk factors with unproven cut-off values, specific risk factor evaluation should 
be done, with metabolic risk assessment combined with parameters of inflammation and 
nutrition to fully assess the real systemic impact of metabolic derangements in PD. 
The euglycemic hyperinsulinemic clamp is regarded as the reference method for insulin 
sensitivity assessment (58, 59). However, this method is expensive and not suitable to use in 
clinical practice. Homeostasis model assessment (HOMA-IR) is easy to perform, and was 
validated as a valuable alternative of measuring insulin resistance, in a static state, both in 
non-CKD patients (60, 61), in patients with CKD stages 3 and 4 (62, 63) and in CKD patients 
on dialysis (64). A single study has evidenced that insulin resistance evaluated by HOMA-IR 
is a predictor of cardiovascular disease in PD patients (65), however the specific role of 
wasting, obesity, peritoneal glucose absorption and small solute transport was not addressed.  
It was already established that insulin resistance in CKD patients has likely contributions from 
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uremic toxins, inflammation, protein-wasting, adipokines, metabolic acidosis and vitamin D 
deficiency that lead to acquired defects in the insulin-receptor signalling pathway (66). In order 
to evaluate the potential benefit of a therapeutic intervention targeting insulin resistance in PD 
patients, investigations should first clarify the sources of insulin resistance in this particularly 
population. What causes insulin resistance in PD: protein-wasting or obesity? Future 
investigations about insulin resistance in PD should assess the clinical relevant associations 
with nutritional status, and further clarify the potential role of peritoneal glucose absorption and 
peritoneal membrane fast transport status.  
Adipokines have also been implicated in the pathogenesis of chronic inflammation and 
insulin resistance associated with obesity, in general population (40, 67). A recent study 
documented the same relationship in a group of patients under hemodialysis (64), showing 
further that insulin resistance indices that incorporate adipokines (like HOMA corrected by 
adiponectin and leptin/adiponectin ratio) were better correlates of glucose-disposal rate 
measured by hyperinsulinemic euglycemic clamp. Similar studies in PD field are lacking. Leptin 
contributes to endothelial dysfunction, atherosclerosis and insulin resistance, and adiponectin 
has insulin-sensitizing, anti-inflammatory and anti-atherogenic effects (40, 41). In line with this 
view, leptin/adiponectin ratio was been recently proposed as a new atherogenic index in type 
2 diabetic patients without CKD. That concept has been supported by recent investigations 
that evidenced a strong correlation between pulse wave velocity and carotid intima-media 
thickness with leptin/adiponectin ratio (68, 69). This ratio is also markedly elevated in 
peritoneal dialysis patients, and one singly study demonstrates an association with mortality 
(70). However, this study was unable to assess the potential role of peritoneal glucose 
absorption and peritoneal membrane transport status on adipokines profile.  
The impact of body composition on adipokines is another relevant aspect in PD that 
was not addressed by any clinical investigation until now. This is a major question when we 
are evaluating patients with CKD because both obesity and protein-wasting will alter the 
normal regulation of adipokines (71-73). There is experimental evidence that adiponectin may 
be a reflection or induce protein wasting, by stimulating energy expenditure (72). Once more, 
the absence of knowledge about patient´s body composition can be a bias that explains the 
contradictory results about adiponectin and outcomes in patients with CKD (70, 74-78), and 
this issue needs to be clarified in future investigations. 
Nutritional assessment should be part of routine care in dialysis patients (79, 80) as 
protein wasting is common in end stage renal disease patients (81, 82) and is a major 
contributing factor to morbidity and mortality in patients under dialysis (12, 83). The first large 
scale cross-sectional comparison study of nutritional status between patients on peritoneal 
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dialysis and hemodialysis, evidenced that PD patients had significantly lower albumin levels, 
and a higher proportion of malnutrition by subjective global assessment (42.3% versus 30.8%) 
(84). Serum albumin robustly associates with death and hospitalization in ESRD patients under 
dialysis (85), is easily and reproducibly measured and responds to appropriate interventions 
(86). However, a recent investigation performed in a cohort of incident and prevalent dialysis 
patients (87) evidenced that serum albumin correlated poorly with several other markers of 
nutrition status and therefore, the authors concluded, that its value as a reliable marker of 
nutritional status in ESRD patients is limited. For that reason, comparative studies on 
nutritional status between patients under hemodialysis and peritoneal dialysis that rely on 
serum albumin levels should be carefully interpreted.  In fact, no single marker of nutrition 
status has been judge to be the best to evaluate CKD patients. For that reason, a panel of 
experts have recently recommended the simultaneous use of biochemical criteria; evidence of 
low body weight, reduced body fat or weight loss; a decrease in muscle mass and low protein 
or energy intake, in order to diagnose protein-energy wasting in CKD patients (81). With the 
widespread use of bioimpedance analysis, a recent multicentre study in contemporary dialyzed 
patients (88) has showed, contrary to previous studies, that protein-wasting is more prevalent 
in hemodialysis patients, while PD patients seem to be relatively protected from catabolism, 
by presenting a significant higher lean tissue index than their matched pairs on hemodialysis. 
Given the controversy about nutritional status in PD, new studies in contemporary PD 
populations should be done with full nutritional status characterization, according to the most 
recent proposed criteria (81). 
The problem of the impact of glucose absorption or membrane fast transport on 
nutritional status was also not adequately addressed. Churchill and colleagues (26) 
hypothesized that fast transporters would had greater loss of proteins in dialysate that would 
not be compensated by protein ingestion, as the greater glucose absorption would lead to a 
decreased appetite. They made that assumption based in the fact that dialysate protein and 
albumin loses at baseline were higher in fast transporters, and that serum albumin was 
significant lower, when compared with others transport categories. However, baseline 
subjective global assessment, lean body mass percentage and normalized protein catabolic 
rate (nPCR) were similar across peritoneal transport categories, and nPCR was not different, 
in a 18 months follow up, between fast and non-fast transporters. Another study documented 
the same correlation between membrane transport and albumin, but not between membrane 
transport and overall nutritional status in PD patients (89). New studies about nutritional status 
evaluation in fast transporters are needed in order to understand if those patients are more 
susceptible to protein-wasting or if they are a high risk group for obesity. Given the fact that 
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systemic inflammation is an independent predictor of survival in PD patients (90), its 
association with obesity and insulin resistance should also be clarified, as there is no 
knowledge yet about the factors that trigger systemic inflammation in these patients. This is 
even more crucial to investigate, as the Global Fluid Study (90) has evidenced that systemic 
and intraperitoneal cytokine networks are dissociated, with the second one being the most 
important determinant of small-solute transport status, without affecting survival. 
Finally, as cardiovascular disease is the first cause of mortality in PD, future studies should 
focus on its relationship with nutritional status. Such a study would clarify if the concept of 
reversal epidemiology, explained by a high prevalence of protein-energy-wasting is applicable 
to PD patients, or if obesity and insulin resistance are in fact the major determinants of 
cardiovascular events, as in the general population. 
 
4. Structural and functional changes of the peritoneal membrane with time on PD 
Dialysate hypertonicity, acidic pH, the presence of glucose degradation products, high 
concentrations of lactate (91, 92) and glucose itself (93-95) contributes to structural alterations 
that occur in the peritoneal membrane with time on PD, in a complex process known by 
epithelial-to-mesenchymal transition (EMT) (96). Yanez-Mo et al. (96) demonstrated that 
peritoneal mesothelial cells showed a progressive loss of epithelial characteristics and 
acquired a fibroblast-like phenotype. According to that process, epithelial cells lose polarity, 
cell-cell contacts and undergo a dramatic remodelling of their cytoskeleton. A portion of these 
fibroblast-like cells of mesothelial origin invade the submesothelium stroma, because of their 
increased migratory capacity, and contribute to PD induced fibrosis of the peritoneum, in a 
process that involves TGF-β1 signaling. However, fibrosis is not the only structural alteration 
evidenced by the peritoneal membrane with time on PD. In parallel with fibrosis, the peritoneum 
shows an increase in angiogenesis, in a process that involves vascular endothelial growth 
factor (VEGF) production by the non-epithelioid, fibroblast-like cells (97).  
With time on PD, all this structural alterations will translate into functional changes, with 
the loss of ultrafiltration capacity of the membrane being the final step (98, 99). The 
angiogenesis process will translate in a progressive higher small solute transport rate, with an 
acquired fast transport peritoneal membrane status (97). This fast transport status is 
responsible for a faster osmotic gradient dissipation and will promote a decrease in water 
transport through the ultra-small pores (100). With progression of submesothelial fibrosis, a 
decreased in peritoneal membrane hydraulic conductance will occur, restricting further the 
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water transport trough the aquaporins, and lowering the membrane osmotic conductance to 
glucose (101, 102).  
As peritoneal biopsies are not routinely performed in clinical practice, structural alterations 
are hardly measured in the clinic. The above mentioned correlations between structure and 
function allow for clinical assessment of the peritoneal membrane characteristics, through a 
peritoneal equilibration test, and are fundamental to monitor, as this will guide PD prescription.    
4.1. Functional evaluation of peritoneal membrane 
The original peritoneal equilibration test (PET) proposed by Twardowski (103) 
evaluates the capacity of the peritoneal membrane to transport solutes and its ability to 
generate ultrafiltration. However, this test does not provide sufficient information to 
discriminate between causes of ultrafiltration failure. To answer that question, a modified PET, 
was proposed (104). This test, using 3.86% glucose solution instead of 2.27% glucose 
solution, not only provides better information on ultrafiltration (because the larger drained 
volume makes the result less subject to measurements errors, and is more sensitive for 
detecting clinically significant ultrafiltration failure), but also allows the sodium sieving 
measurement, as an indirect estimation of the magnitude of water transport through the 
aquaporins. However, it is important to bear in mind that an apparent reduction in sodium 
sieving can also be caused by an increase in peritoneal small solute diffusion, or by a reduction 
in the ultrafiltration coefficient of the peritoneal membrane (105). Therefore, a reliable tool to 
quantify both the peritoneal free water transport and small-pore solute and water transport 
would be of great practical importance.  
Recently, two methods have been developed to measure free water transport in PD 
patients (106, 107), both validated by computer simulations using the three-pore model (108). 
The standard permeability analysis test by Smit (107) is accurate to measure both free water 
transport and small-solute transport, but involves several different measurements and 
sophisticated calculations, making this test difficult to apply in clinical practice.  The mini-PET 
by La Milia (106) is a simple and accurate method that allows measurement of free water 
transport, but overestimates the dialysate-to-plasma ratio of creatinine (D/Pcreatinine), since it is 
measured at 60 minutes, and the D/Pcreatinine at 60 minutes is not equivalent to the D/Pcreatinine 
measured in a 4-hour PET (109). To overcome this limitations, Cnossen et al. (110), performed 
a study in which they compared, in 10 prevalent PD patients, small solute transport assessed 
in a 4-hour, 3.86% glucose PET, with temporary complete drainage of the peritoneum after 1 
hour (allowing for simultaneous quantification of free water transport), concluding that the 
interim step did not influence the D/Pcreatinine  measured at 4 hours. This new method is simple 
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to use in clinical practice and overcome the limitations of the mini-PET (106) that has only one 
hour of duration. For that reason, this new and promising approach, should be re-evaluated, 
in a larger PD population, in order to assess its clinical relevance. 
4.2. Effluent biomarkers as an early sign of peritoneal membrane alterations: 
controversies 
The use of biomarkers as an early sign of peritoneal membrane alterations is currently 
under debate (111-113), especially because clinical factors cannot give an accurate individual 
prediction for peritoneal sclerosis (101). In a very recent research (102), patients with 
encapsulating peritoneal sclerosis (EPS) presented, compared with long-term PD controls, an 
early loss of both ultrafiltration capacity and sodium sieving two years before the onset of overt 
EPS. The loss of ultrafiltration capacity in EPS patients was disproportionate to the increase 
in MTAC of creatinine, and suggested an uncoupling between peritoneal fluid and solute 
transport.  In a multivariate analysis, the loss of sodium sieving was a powerful and 
independent risk factor associated with encapsulating peritoneal sclerosis, outperforming other 
clinical variables as younger age at dialysis onset, longer PD duration, lower residual renal 
function, beta blocker use and peritonitis rates (102). Since a reduced free water transport is 
the most powerful indicator for the development of EPS, and is not simply explained by an 
increase in vascular capillary surface, it is important to search for a biomarker that correlates 
both with ultrafiltration and free water transport, and not only with membrane small solute 
transport status. The most recent studies about peritoneal effluent biomarkers compared 
cytokines in patients who developed EPS with PD controls, and present contradictory results 
(111-113). Besides, none of them has explored the associations between cytokines measured 
in the effluent and water transport pathways, namely with free water transport that could be 
significantly compromised several years before EPS onset (102), and for that reason, more 
informative, allowing a timely diagnosis of peritoneal membrane dysfunction. 
Hepatocyte growth factor (HGF) is known to play a crucial role in the repairing process 
of tissues and preventing organ fibrosis (114-117). Human peritoneal mesothelial cells 
constitutively synthetize HGF, and treatment of human peritoneal mesothelial cells with HGF 
blocks high glucose-induced epithelial-to-mesenchymal transition (93). Recent clinical 
research underscores that the protective role of HGF in peritoneal fibrosis is due to inhibition 
of transforming growth factor β1 signaling (117). One single clinical study compared effluent 
HGF concentration according to small solute transport status (118). However, the authors did 
not explore any association between effluent HGF and ultrafiltration failure, neither with water 
transport pathways quantification. It is thus relevant to increase the knowledge on HGF clinical 
value in patients under PD, as it may possible point to new diagnostic opportunities and 
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therapeutic avenues. Therefore, clinical investigation under this subject is mostly important 
and needed. 
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I I I .  AIMS AND OUTLINE OF THE THESIS 
 The aim of this thesis was to investigate the systemic impact of intrinsic aspects of the 
peritoneal dialysis technique, such as peritoneal glucose absorption, peritoneal membrane 
transport status, and peritoneal dialysis modality on residual renal function preservation, 
maintenance of phosphate control, and development of protein-energy wasting, obesity and 
insulin resistance in a population of incident and prevalent patients under peritoneal dialysis. 
At the same time, this thesis focused also on the functional evaluation of the peritoneal 
membrane, establishing a new peritoneal equilibration test to evaluate simultaneously small 
solute transport and water transport, and explores new peritoneal effluent biomarkers that 
could timely signalize peritoneal membrane deterioration, even before clinically relevant 
ultrafiltration failure develops. 
In chapter V.I, the factors that influenced residual renal function decline in our incident 
peritoneal dialysis population were investigated. We aimed to test the hypothesis that the 
previous renal replacement therapy modality, specifically transition to PD after renal graft 
failure, impacts residual renal function loss. 
In chapter V.II, the peritoneal membrane phosphate transport status was defined, in a 
large prevalent peritoneal dialysis population, and its associations with hyperphosphatemia, 
phosphate peritoneal clearance and peritoneal dialysis modality were investigated. We tested 
the hypothesis that phosphate serum levels are dependent on peritoneal membrane 
phosphate transport status, with a clinically relevant association with dialysis regimens. 
In chapter V.III, the nutritional status of a contemporary peritoneal dialysis population, 
in treatment in our Unit, was investigated with the simultaneous use of different nutritional 
assessment tools, including biochemical criteria, body composition assessment using 
anthropometry, and characterization of dietary intake. 
In chapter V.IV.I we aimed to test the hypothesis that leptin/adiponectin ratio, in patients 
under peritoneal dialysis, is dependent on patient´s body composition, and impacts on 
cardiovascular mortality. In this prospective study, the impact of adipokines profile as a 
predictor of cardiovascular events was investigated, taking into consideration patient´s body 
composition assessed by bioimpedance analysis and the potential roles of peritoneal glucose 
absorption and peritoneal membrane small solute transport status. The relationship between 
cardiovascular disease and nutrition status in PD patients was assessed. The value of body 
mass index to measure obesity was evaluated against full body composition characterization 
with bioimpedance analysis. Finally, the potential roles of peritoneal glucose absorption and 
fast transport status on obesity development and adipokines profile were also investigated. 
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In chapter V.IV.II, insulin resistance, using homeostasis model assessment method 
(HOMA-IR) and HOMA corrected by adiponectin (HOMA-AD), was evaluated in a group of 
non-diabetic, contemporary patients, under peritoneal dialysis. Our aim was to test the 
hypothesis that insulin resistance is dependent on body composition parameters, peritoneal 
glucose absorption and peritoneal membrane small-solute transport status. Fast transporters 
were particularly examined, since there are some concerns in the contemporary literature, 
about the metabolic systemic consequences associated with a fast membrane transport status. 
In chapter V.V.I, functional characterization of the peritoneal membrane was 
performed in a multicentre study using a new peritoneal membrane equilibration test (the 
«Two-in-one Protocol»).  Small-solute transport status, free water transport and small-pore 
ultrafiltration were simultaneously assessed and quantified. Ultrafiltration failure causes were 
analysed. The relationship between the different water transport pathways was assessed, both 
in situations with and without ultrafiltration failure. 
In chapter V.V.II, we tested the hypothesis that hepatocyte growth factor (HGF), a 
biomarker with important roles in the repairing process of tissues and organ fibrosis prevention, 
signalizes peritoneal membrane derangements. Therefore, the relationship between effluent 
HGF and free water transport and small solute transport were investigated. Patients with fast 
transport status and free water compromise were particularly studied, since they are 
considered a high risk group in terms of peritoneal membrane dysfunction. 
Chapter VI includes a general discussion. Future investigations and perspectives are 
also debated.  
 Chapter VII includes a summary of the most important conclusions.  
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IV.  METHODS 
Specific methodological issues in this investigation are highlighted. 
Concerning nutritional assessment, the investigations performed involved several 
tools, in order to achieve an accurate nutritional assessment of the studied PD patients, 
according to the most recent criteria proposed by the International Society of Renal Nutrition 
and Metabolism (81).  
In the first study performed (chapter V.III), nutrition status was assessed by Subjective 
Global Assessment (SGA) and by a nutrition status score (NSS) based on biochemical and 
anthropometric measurements. The SGA was performed by a single trained observer, who 
was blinded for the biochemical results of the patients. SGA integrates a four-item, 7-point 
scale, based on history of weight change, appetite, gastrointestinal symptoms and physical 
examination of body fat and muscles (119, 120). An SGA score of 6 – 7 indicates a well-
nourished individual (“A”); 3-5 a mildly-to-moderately malnourished individual (“B”); and 1-2, a 
severely malnourished individual (“C”). Anthropometric measurements were made on biceps, 
triceps, and subscapular skinfold thickness by a single observer, immediately after peritoneal 
dialysate drainage, using a conventional Harpenden skinfold caliper. Each measurement was 
repeated three times, and the average result was registered. Mid-arm circumference (MAC) 
was also measured, and mid-arm muscle circumference (MAMC) was calculated using the 
formula (121): MAMC (mm) = MAC (MM) – 3.14 x Triceps Skinfold (mm). Body density was 
calculated based on the sum of skinfold thickness values, using the equations of Durnin and 
Womersly (122). Fat mass and lean body mass were obtained from calculated body density 
and body weight. The NSS used consisted of eight components: body mass index, percentage 
of ideal body weight (calculated according to Butheau and Metropolitan Life Insurance 
Company formulas), triceps and subscapular skinfold thickness, MAMC, serum albumin, total 
lymphocyte count and subjective physical examination. Skinfold measurements and MAMC 
were compared with the 50th percentile for the appropriate age and sex, and were expressed 
as percentages (123).  
In 2009 the PD Unit adopted, as a standard, the use of whole body bioimpedance in 
order to evaluate patient´s body composition, using the Body Composition Monitor device 
(BCM®, Fresenius Medical Care, Bad Homburg, Germany). For that reason, in the subsequent 
investigations performed (chapters V.IV.I and V.IV.II), anthropometric measurements were 
no longer used, and were substituted by bioimpedance analysis. The bioimpedance method 
applied was validated by isotope dilution methods (124), by accepted reference body 
composition methods (125) and by extensive clinical assessment of the hydration state (126). 
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Body composition assessments were done with full abdomen during the PET procedure. Lean 
tissue index (LTI), fat tissue index (FTI), relative fat mass (rel.FM), body cell mass (BCM) and 
relative over hydration (rel.OH) were measured. Only measurements achieving simultaneously 
high quality (>90%) and lower error percentage (<35%), showing an inverted U curve, in the 
device monitor, were considered valid. Due to biophysical reasons, the bioimpedance 
spectroscopy does not measure sequestered fluid in the trunk (127), therefore the presence 
or absence of PD fluid in the abdomen does not influence body composition parameters related 
with nutritional status (128). Women with relative fat mass above 30% and men with relative 
fat mass above 25% were considered obese (56). The values for LTI were compared to an 
age and gender-matched reference population and according to this, patients with LTI inferior 
to the 10th percentile were considered to have protein wasting (129). Patients that 
simultaneously presented with relative fat mass <10% and LTI < reference range, were 
characterize as having protein-energy wasting (81). 
 Concerning biochemical assessments, albumin was measured by the same 
methodology in the different studies performed (bromocresol green - Cobas Integra 800 – 
Roche Diagnostics). Serum leptin and adiponectin, were measured using the same enzyme-
linked immunosorbent assays in the different studies performed (Mediagnost, Reutlingen, 
Germany). 
 In the chapter V.IV.II, insulin resistance was assessed using homeostasis model 
assessment (HOMA-IR), homeostasis model assessment correct by adiponectin (HOMA-AD) 
and by leptin/adiponectin ratio, according to the following equations (64): HOMA-IR = fasting 
serum insulin (µU/mL) x fasting serum glucose (mg/dL)/405; HOMA-AD = fasting serum insulin 
(µU/mL) x fasting serum glucose (mg/dL)/adiponectin (µg/mL); leptin/adiponectin ratio = leptin 
(ng/mL)/adiponectin (µg/mL). In order to measure plasma insulin and plasma glucose without 
a significant interference from peritoneal glucose absorption, the preceding overnight dwell 
was standardized to 1.36% glucose solution in all patients (31). Venous blood samples were 
obtained after an 8-10 hours overnight fasting period, in the morning of the peritoneal 
equilibration test (PET). Blood samples were drawn after the last dwell drainage and before 
starting the PET. Insulin was measured by a sandwich assay on an electrochemiluminescence 
(ECLIA) immunoassay analyzer (Cobas E 170 – Roche Diagnostics GmbH). Patients with 
HOMA-IR ≥ 2.2 were considered to present insulin resistance, as this value corresponds to 
HOMA-IR percentile 50 in the larger validation study about HOMA-IR against the euglycemic, 
hyperinsulinemic clamp in non-diabetic patients (60).  
 In chapters V.IV.I and V.IV.II, peritoneal glucose absorption was calculated by 
subtracting the 24-h drained glucose (measured) from the total glucose influx by the dialysate. 
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 In chapter V.V.I a new peritoneal equilibration test (the “Two-in-One Protocol”) was 
tested in a large population of incident and prevalent patients under PD. This protocol allowed 
free water transport (FWT) quantification, beyond a simple calculation of sodium sieving. None 
of the patients evaluated had peritonitis during the study, or the preceding 6 weeks. During the 
procedure, PD solutions low in glucose degradation products were used, according to the 
individual patient’s prescription. The volume of dialysis solution was determined by weight, 
without flushing the system and before filling the peritoneum. Blood and dialysate samples 
(each approximately 10 mL) were taken at instillation of the dialysate and after 60 and 240 
minutes. At 60 minutes, an additional measurement of ultrafiltration (UF) by total drainage of 
the peritoneal cavity was performed. This drained volume was weighed and then immediately 
re-infused. Finally, after 240 minutes, the peritoneal cavity was drained and the volume 
obtained was weighed. During the study PET, FWT was calculated as follows: FWT (mL) = 
Total UF volume at 60 minutes (mL) – UF through the small pores at 60 minutes (mL). The UF 
through the small pores (SPUF) at 60 minutes was calculated as follows: SPUF (mL) = [NaR 
(mmol) × 1000] / PNa, where NaR (mmol) is sodium removal and PNa is the sodium 
concentration in plasma assessed by indirect ion-selective electrodes. The NaR was 
calculated as [Dialysate V at 60 minutes (L) × Dialysate Na at 60 minutes (mmol/L)] – [Dialysate 
V instilled (L) × Dialysate Na at 0 minutes (mmol/L)]. Using a simple algorithm, a correction for 
FWT, as described by Venturoli and Rippe (108), was also performed: FWTcorrected = Total UF 
at 60 minutes + 15 – 0.92 × SPUF, where the “15” represents cumulative lymphatic absorption 
during 60 minutes (18 mL) minus the cumulative UF through the large pores during 60 minutes 
(approximately 3 mL). The FWT fraction was also evaluated. PETs with an ultrafiltered volume 
≤ 400 mL/4h were considered to represent ultrafiltration failure (UFF) (130). 
 Functional evaluation of the membrane was performed in all investigations using the 
Two-in-One PET. Creatinine and sodium were measured in both plasma and dialysate. 
Glucose was assessed in dialysate. Creatinine and glucose were measured using standard 
automated analyser techniques. For creatinine, the Jaffé compensated method was used. The 
dialysate creatinine concentration was corrected for interference by glucose according to our 
laboratory standards. Sodium in dialysate and plasma was measured using indirect ion-
selective electrodes. 
 In chapter V.V.II, a new effluent biomarker was investigated in order to explore its 
associations with small solute transport and membrane water transport pathways.  Effluent 
HGF was determined by ELISA technique according to the manufacturer’s instructions (IBL – 
Immuno-Biological Laboratories Co. Ltd). The intra and inter-assay variations were 
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respectively 8,8% and 10,0%. The sensitivity was 11pg/mL. The assay was considered highly 
specific for the cytokine, and no significant cross-reactivity was observed. 
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V –  Results 
 
V.I. Predictors of residual renal function loss in PD patients 
Bernardo A, Fonseca I, Rodrigues A, Carvalho MJ, Cabrita A. Predictors of residual renal 
function loss in peritoneal dialysis: is previous renal transplantation a risk factor? Adv Perit 
Dial. 2009;25:110-4. 
 
Short Summary 
Residual renal function (RRF) plays a major role in dialysis patient´s clinical outcomes, and for 
that reason, preservation of residual renal function loss is an important goal in peritoneal 
dialysis population. 
In this study we investigated the factors associated with RRF decline in a population of 148 
consecutive patients treated in our Unit. 
Our study showed that RRF was not significantly different between patients who started 
peritoneal dialysis (PD) as theirs first option, and those who started PD after renal 
transplantation. Transfer from hemodialysis was the only significant predictor of baseline 
anuria. After the start of PD, diabetes was the only independent predictor of anuria. Age, 
gender, PD after renal graft failure, PD modality and fast transport status were not predictors 
of anuria. 
This investigation allowed us to conclude that diabetes was the most important determinant of 
the time course of RRF decline in our population, and that peritoneal dialysis after renal 
transplant failure can offer similar short-term RRF protection compared to that seen in PD-first 
patients. 
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V –  Results 
 
V.II. Peritoneal membrane phosphate transport status 
Bernardo AP, Contesse SA, Bajo MA, Rodrigues A, Del Peso G, Ossorio M, Cabrita A, Selgas 
R. Peritoneal membrane phosphate transport status: a cornerstone in phosphate handling in 
peritoneal dialysis. Clin J Am Soc Nephrol. 2011 Mar;6(3):591-7. doi: 10.2215/CJN.06960810. 
Epub 2010 Nov 29. 
 
Short Summary 
Phosphate control impacts dialysis outcomes, but few studies have addressed the importance 
of PD modality and peritoneal membrane transport status concerning dialytic phosphate 
clearance. 
With this clinical investigation, we aimed to define peritoneal phosphate transport in peritoneal 
dialysis patients, and to explore its association with hyperphosphatemia, phosphate clearance 
and PD modality. 
We evaluated 264 patients treated in Peritoneal Dialysis Unit from La Paz University Hospital. 
We were able to show that residual renal function was independently, negatively, associated 
with hyperphosphatemia and that, in anuric patients, peritoneal membrane phosphate 
transport status was the only significant predictor of hyperphosphatemia. We also evidenced 
that phosphate and creatinine peritoneal membrane transport status characterization can differ 
in the same patient, and that CAPD treatment is associated with an increase in phosphate 
clearance of 13.6% among phosphate slow-average transporters, and 38.4% among 
phosphate slow transporters. 
Our study contributes to our understanding of peritoneal phosphate clearance by highlighting 
the importance of establishing peritoneal membrane phosphate transport status. In 
hyperphosphatemic or anuric patients, the decision on the optimal PD modality should also 
take into account peritoneal phosphate transport characteristics, beyond urea Kt/V and 
peritoneal creatinine clearance. Increasing dwell times or transfer to CAPD could be effective 
strategies to improve phosphate handling in patients with inadequate phosphate control on 
APD. 
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V –  Results 
 
V.III. Evaluation of nutritional status in contemporary PD patients 
Bernardo AP, Fonseca I, Rodrigues A, Carvalho MJ, Cabrita A. Overweight rather than 
malnutrition is widely prevalent in peritoneal dialysis patients. Adv Perit Dial. 2009;25:119-24. 
 
Short Summary 
Protein wasting is common among chronic kidney disease patients under dialysis, contributing 
to morbidity and mortality. Few studies evaluate the nutritional status of contemporary 
peritoneal dialysis (PD) patients. 
In this clinical investigation, we studied 57 PD patients treated in our Unit. We assessed their 
nutritional status according to the most recent criteria of International Society of Renal Nutrition 
and Metabolism. 
We concluded that overweight rather than malnutrition was widely prevalent in our population, 
but we could not find any association between overweight and obesity with demographic or 
modality related factors, neither with fast transport, nor with markers of systemic inflammation. 
However, we documented a potential atherogenic lipid profile in the overweight group, which 
can be seen as a potential risk factor for cardiovascular disease. This clinical investigation 
brings up de question whether overweight is a protective condition, associated with lower 
comorbidity and a lower metabolic rate, or whether it instead represents a clinical menace. In 
our subsequent clinical investigations (chapter V.IV.I and V.IV.II) we tried to specifically 
address this issue. 
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V –  Results 
 
V.IV. The impact of peritoneal glucose absorption and fast transport status on obesity, 
insulin resistance and new cardiovascular events in PD patients. 
 
V.IV.I Bernardo AP, Fonseca I, Oliveira JC, Santos O, Carvalho MJ, Cabrita A, Rodrigues A. 
Adipokines in peritoneal dialysis: relevant clinical impact according to body composition. Ther 
Apher Dial. 2015 Apr;19 (2):144-53. doi: 10.1111/1744-9987.12239. Epub 2014 Nov 3. 
 
V.IV.II Bernardo AP, Oliveira JC, Santos O, Carvalho MJ, Cabrita A, Rodrigues A. Insulin 
Resistance in nondiabetic peritoneal dialysis patients: associations with body composition, 
peritoneal transport and peritoneal glucose absorption. Clin J Am Soc Nephrol. 2015 Oct 27. 
pii: CJN.03170315. [Epub ahead of print]. 
 
 
Short Summary (manuscript V.IV.I) 
As in general population, overweight is widely prevalent in peritoneal dialysis patients. Being 
a risk factor for cardiovascular disease in general population, the clinical impacts of obesity 
and overweight are uncertain in peritoneal dialysis patients. Also, adipokines impact on clinical 
outcomes is not adequately addressed in peritoneal dialysis patients, as previous studies have 
not taken into account important specificities of body composition of this particular population. 
We aimed to investigate the impact of leptin/adiponectin ratio (LAR) as a predictor of 
cardiovascular events in PD, taking into consideration patient´s body composition and the 
potential role of glucose load. We prospectively followed 66 patients for 47.0±28.2 months. 
New cardiovascular events were evaluated and body composition parameters were assessed 
by bioimpedance analysis. 
With this clinical investigation, we were able to document that body mass index is an inaccurate 
method to classify obesity in PD, since it underestimates its prevalence, compared with body 
composition assessment using bioimpedance analysis. We confirmed our previous 
observation that obesity is widely prevalent in contemporary PD patients, being present in 
73.4% of our population. Fat tissue index was higher in patients with cardiovascular events, 
but body composition parameters related with lean mass were similar between the two groups. 
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A link between obesity and new cardiovascular events was also documented, since the 
percentage of patients with obesity was significantly higher in patients who suffered new 
cardiovascular events compared with patients without new cardiovascular events (93.8% 
versus 66.7%, P=0.029). We also were able to document that LAR is determined by relative 
fat mass and lean tissue index, so that a higher leptin/adiponectin ratio is only significantly 
associated with cardiovascular events in peritoneal dialysis patients without protein-wasting. 
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V –  Results 
 
Short Summary (manuscript V.IV.II) 
Insulin resistance has been associated with cardiovascular disease, the major cause of death 
in peritoneal dialysis patients. However, few studies have addressed the impact of fast 
transport status, dialysis prescription and nutritional status on insulin resistance development 
in peritoneal dialysis patients. 
With this clinical investigation, we aimed to test whether insulin resistance is associated with 
obesity parameters, peritoneal transport rate and peritoneal glucose absorption. 
We evaluated all the 51 non-diabetic patients currently treated in our Unit. Insulin resistance 
was evaluated with homeostasis model assessment method (HOMA-IR), HOMA correct by 
adiponectin (HOMA-AD) and with leptin/adiponectin ratio (LAR). Daily peritoneal glucose 
absorption was measured, and body composition parameters were assessed using 
bioimpedance analysis. 
We found significant correlations between the several insulin resistance indices and body 
composition parameters related with fat mass in obese patients, but not in non-obese group. 
We didn´t found any association between insulin resistance indices and small-solute transport 
status, neither with peritoneal glucose absorption. An insulin resistant state was documented 
in 18 patients (35.3%), who presented a significant higher prevalence of obesity (84.6% versus 
47.8%, P=0.04), but similar prevalence of protein-wasting (38.5% versus 13%, P=0.11). There 
were no significant differences in peritoneal glucose absorption, body composition parameters 
and insulin resistance indices between fast transporters and patients who present others 
peritoneal small-solute transport categories. Fat tissue index and leptin/adiponectin ratio were 
independent predictors of HOMA-IR, in a multivariate analysis adjusted for glucose absorption 
and small-solute transport (r=0.82, P<0.001). 
In this clinical investigation, we were able to clarify that insulin resistance in non-diabetic 
peritoneal dialysis patients is associated with obesity and leptin/adiponectin ratio, 
independently of glucose absorption and small-solute transport status. Fast transporters, 
under updated therapy regimens, have no higher risk of obesity or insulin resistance. 
In practice, the two studies presented in chapter V.IV, put in evidence that the concept of 
reversal epidemiology that was found in several hemodialysis populations may not be applied 
to PD patients. As in general population, in patients under peritoneal dialysis, obesity is related 
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with insulin resistance, and patients with insulin resistance, namely with higher 
leptin/adiponectin ratio, are more prone to suffer from cardiovascular events. 
 
 
 
                                                            Metabolic derangements in peritoneal dialysis: 
                                                            Systemic impact and functional expression of peritoneal membrane 
 
80 
 
 
 
 
 
                                                            Metabolic derangements in peritoneal dialysis: 
                                                            Systemic impact and functional expression of peritoneal membrane 
 
81 
 
 
 
 
 
                                                            Metabolic derangements in peritoneal dialysis: 
                                                            Systemic impact and functional expression of peritoneal membrane 
 
82 
 
 
 
 
 
                                                            Metabolic derangements in peritoneal dialysis: 
                                                            Systemic impact and functional expression of peritoneal membrane 
 
83 
 
 
 
 
 
                                                            Metabolic derangements in peritoneal dialysis: 
                                                            Systemic impact and functional expression of peritoneal membrane 
 
84 
 
 
 
 
 
                                                            Metabolic derangements in peritoneal dialysis: 
                                                            Systemic impact and functional expression of peritoneal membrane 
 
85 
 
 
 
 
 
                                                            Metabolic derangements in peritoneal dialysis: 
                                                            Systemic impact and functional expression of peritoneal membrane 
 
86 
 
 
 
 
 
                                                            Metabolic derangements in peritoneal dialysis: 
                                                            Systemic impact and functional expression of peritoneal membrane 
 
87 
 
 
 
 
 
                                                            Metabolic derangements in peritoneal dialysis: 
                                                            Systemic impact and functional expression of peritoneal membrane 
 
88 
 
V –  Results 
 
V.V. Functional characterization of peritoneal membrane 
 
V.V.I Bernardo AP, Bajo MA, Santos O, del Peso G, Carvalho MJ, Cabrita A, Selgas R, 
Rodrigues A. Two-in-one protocol: simultaneous small-pore and ultrasmall-pore peritoneal 
transport quantification. Perit Dial Int. 2012 Sep-Oct;32(5):537-44. Epub 2012 Mar 1. 
 
V.V.II Bernardo AP, Oliveira JC, Santos O, Carvalho MJ, Cabrita A, Rodrigues A. Hepatocyte 
growth factor signalizes peritoneal membrane failure in peritoneal dialysis. BMC Nephrol. 2014 
Dec 17;15:201. doi: 10.1186/1471-2369-15-201. 
 
Short Summary (manuscript V.V.I) 
Glucose, the main osmotic agent used in peritoneal dialysis (PD), contributes to peritoneal 
membrane structural changes, with time on the technique. This structural alterations will 
translate into functional changes, with the loss of ultrafiltration capacity of the membrane being 
the final step. Reduced free water transport (FWT) contributes to ultrafiltration failure and 
should be seen as a sign of more severe functional deterioration of the peritoneal membrane. 
However, the modified peritoneal equilibration test (PET) does not allow to quantify FWT 
trough the aquaporins. 
The aim of our clinical investigation was to quantify simultaneously, in a large PD population, 
small solute transport, FWT and small-pore ultrafiltration using a single PET procedure. We 
evaluated 70 patients attending at Peritoneal Dialysis Units from Hospital de Santo António – 
Porto, and Hospital Universitário La Paz – Madrid. Our investigation shows that total 
ultrafiltration correlated better with effectively measured FWT than with any other indirect 
measurement of sodium sieving. FWT and total ultrafiltration, both decline with time on PD. 
Eleven patients were diagnosed with ultrafiltration failure, presenting significant higher small-
solute transport parameters and lower FWT. The water transport trough small-pores correlates 
positively with FWT in patients without ultrafiltration failure, but negatively in patients with 
ultrafiltration failure. 
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In this clinical investigation we tested a new PET (the “Two-in-One Protocol”), in a large PD 
population, showing that measurement of FWT and small-pore ultrafiltration quantification is 
feasible in a single PET procedure. This study also contributes to clarify additional causes of 
ultrafiltration failure, beyond increased effective capillary surface. The proposed Two-in-One 
Protocol is a simple method for timely detection of membrane failure, capable of document the 
most common peritoneal membrane dysfunctions, and can be used in routine annual PD 
patient management, so that therapy can be properly adjusted. 
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V –  Results 
 
Short Summary (manuscript V.V.II) 
Ultrafiltration failure is still a challenging complication of peritoneal dialysis, and its prevalence 
increases with time on PD. In long-term patients, ultrafiltration failure is more severe and often 
associates with free water transport (FWT) compromise. Since it is known that increased 
submesothelial fibrosis is an early and progressive lesion ultimately associated with 
ultrafiltration failure and free water transport compromise, the search for an effluent marker 
related to membrane fibrosis process, and exhibiting a good correlation with ultrafiltration and 
FWT, would be clinically important. Hepatocyte growth factor (HGF) counteracts peritoneal 
fibrosis, in animal models and in-vitro studies, but no study has ever explored effluent HGF in 
peritoneal dialysis patients with ultrafiltration failure. 
Our cross sectional study enrolled 68 patients treated in our Unit. All the patients performed a 
peritoneal equilibration test according to our “Two-in-One Protocol”. HGF in the effluent was 
also measured. 
A strong negative correlation was documented between HGF and both FWT and total 
ultrafiltration volume. Patients with ultrafiltration failure had higher dialysate HGF, specially the 
patient´s sub-group who presented FWT compromise. 
With this clinical investigation we were able to document that HGF concentration is significantly 
higher among patients with ultrafiltration failure, especially if FWT is impaired, being a potential 
sign of peritoneal membrane deterioration. 
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V I  –  General  Discussion  
 
 Predictors of residual renal function loss and phosphate handling in peritoneal 
dialysis. 
 Nutrition and body composition in contemporary peritoneal dialysis patients: 
clinical relevant associations. 
 Nutritional status and adipokines in peritoneal dialysis patients: relationship with 
cardiovascular events. 
 Insulin resistance in non-diabetic peritoneal dialysis patients: associations with 
body composition but not with peritoneal glucose absorption or peritoneal 
membrane fast transport status. 
 Peritoneal membrane functional evaluation: free water transport quantification 
and the potential value of effluent hepatocyte growth factor to timely 
characterize peritoneal membrane dysfunction. 
 Future investigations. 
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VI.  GENERAL DISCUSSION 
The number of end stage renal disease patients treated by peritoneal dialysis (PD) has 
increased over the last years, all around the world (1). The clinical outcomes in patients under 
PD improved in the last decade (2, 4), and the most recent studies comparing survival in 
peritoneal dialysis and hemodialysis showed similar outcomes in the first years of end stage 
renal disease therapy (2-5). In spite of being a successful end stage renal disease therapy, 
there are inner aspects of the technique that require additional investigation, in order to 
improve further patient´s clinical outcomes, such as metabolic derangements and the systemic 
impact of the functional characteristics of the peritoneal membrane. 
We developed a series of cross sectional and prospective clinical researches, in order 
to investigate the systemic impact of intrinsic aspects of the peritoneal dialysis technique, such 
as peritoneal membrane transport status, peritoneal glucose absorption and peritoneal dialysis 
modality, on residual renal function, phosphate control, body composition and insulin 
resistance development in a population of incident and prevalent patients under peritoneal 
dialysis. At the same time, since the filter is a determining interface between the external 
technique and the internal milieu, this thesis focused also the functional evaluation of the 
peritoneal membrane, by establishing a new peritoneal equilibration test capable of evaluate 
simultaneously small-solute transport and water transport pathways, enabling us to diagnose 
the most common causes of ultrafiltration failure in our patients. We also explored new 
peritoneal effluent biomarkers that could timely signalize peritoneal membrane deterioration, 
even before clinically relevant ultrafiltration failure develops. 
 
Predictors of residual renal function loss and phosphate handling in peritoneal 
dialysis 
Residual renal function (RRF) plays a major role in dialysis patients, whichever the 
modality, but has been much more focused in PD with impact in patient´s survival (13-15). For 
that reason, determining the factors that affect its loss has become an important issue in the 
care of PD patients. Larger body mass index, diabetes, peritonitis episodes, peritoneal 
membrane fast transport status and the use of automated peritoneal dialysis (APD) are some 
of the factors that have been previously associated with residual renal function loss in PD (18-
20). However, results are not consensual and studies frequently exclude patients with a failed 
renal graft, which has becoming one of the most frequent causes of dialysis initiation (131). 
We have evaluated 148 patients consecutively admitted and treated in our Unit, and we have 
explored the factors conditioning RRF decline in our population (chapter V.I). Our results 
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reproduce a previous report from Liao et al. (18), since diabetes was the major determinant of 
RRF decline in the studied population. Importantly, we could not find any association between 
RRF loss and peritonitis rates, peritoneal membrane fast transport status, neither with APD 
use in our population, replicating the findings in previous studies (18, 132, 133). Contradictory 
results have been reported concerning RRF decline in patients that initiate peritoneal dialysis 
after a failed renal transplant. Sasal et al. (134) and Davies et al. (135) reported a more rapid 
loss of RRF in these patients, compared with patients that have never undergone kidney 
transplantation. We, like de Jonge et al. (136), found no difference in the decline of RRF 
between patients starting PD after renal transplant failure and patients starting PD as their first 
renal replacement therapy.  Although the small sample size of the PD after renal transplant 
group could have precluded a statistically significant difference, we hypothesized that our 
policy of slowly tapering the immunosuppressors (immediate withdrawal of the anti-proliferative 
drugs, but slow reduction of calcineurin inhibitors and prednisolone over several months), 
presumably protects renal graft function. 
The robust relationship seen between RRF and survival on PD may be also partially 
explained by the improved control of serum phosphate levels evidenced in patients with 
preserved RRF (22), since a strong correlation between residual renal function and serum 
phosphate concentration has been reported (137). Our study on phosphate handling in PD 
patients (chapter V.II), reproduced the results from Wang study (22), as hyperphosphatemia 
was present in 43.6% of our anuric patients versus 24.2% in patients with RRF (P=0.002), and 
RRF was the only independent predictor of hyperphosphatemia in the 264 studied patients.  
Hyperphosphatemia is a common clinical finding in patients with CKD under dialysis, 
and has emerged as an important factor for cardiovascular mortality in these patients (23-25, 
138-141). Mechanistically, the link between hyperphosphatemia and mortality has been 
attributed to the disseminated vascular calcifications (142) and to several hemodynamic 
disturbances including ventricular hypertrophy, increased blood pressure, increased cardiac 
work and high arterial tensile stress (143). These findings raise the issue of whether dialytic 
phosphate removal might provide a more relevant direct measure of dialysis efficacy and 
adequacy than urea and creatinine clearances, especially when residual renal function is lost. 
In fact, when we focused on anuric patients, peritoneal membrane creatinine transport status 
was not a significant predictor of hyperphosphatemia, but peritoneal membrane phosphate 
transport status (D/P phosphate) was. This is another relevant clinical input of our 
investigation: although peritoneal phosphate clearance was more closely related with 
peritoneal creatinine clearance than with urea clearance,  D/P creatinine was not a sufficiently 
accurate measure to classify patients for peritoneal membrane phosphate transport status, as 
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the characterization of patients concerning phosphate and creatinine transport was quite 
different (47.4% patients were fast/fast average transporters according to phosphate transport, 
but 74.2% were fast/fast average transporters according to creatinine transport). The fact that 
phosphate is mainly an intra-cellular ion (with a slow intra-extra cellular solute transfer rate); 
15% to 20% of phosphate is protein bound and 5% complexes with other ions; its transport 
depends on osmotic, chemical and electrical gradients and also trans-membranous active 
phosphate transporters; and the aqueous layer that surrounds the phosphate molecule, may 
be some of the reasons why phosphate apparently reaches a slowly equilibration across the 
peritoneal membrane than creatinine (144-146). 
Few studies have compared peritoneal phosphate clearance according to peritoneal 
dialysis modality, and the results were not consensual (147-149). These previous studies were 
limited by small sample size and no adjustment for peritoneal membrane transport category. 
Sedlacek et al. (147) and Badve et al. (148), reported that phosphate clearance is higher in 
fast transporters compared with slow transporters in CAPD and APD, when peritoneal 
transport status is defined according to Twardowski categories of D/P creatinine (103) in a 4-
hour, 3.86% glucose PET. Our study (chapter V.II) expands on the work of these groups, 
because we compared phosphate clearance between CAPD and APD, by adjusting for 
peritoneal membrane phosphate transport category. Our data suggests that peritoneal 
membrane phosphate transport status should be considered in order to optimize PD 
prescription, as CAPD was associated with a significant increase in phosphate clearance of 
13.6% among slow-average transporters, and 38.4% among slow transporters, compared with 
APD. 
Our clinical investigation also suggest that focusing only on urea and creatinine for 
assessment of dialysis adequacy may not result in an adequate clearance of phosphate. In 
fact, although more than 97% of our anuric patients had a peritoneal Kt/V of 1.7 or greater, 
and 83.3% had a peritoneal creatinine clearance equal or superior to 45L/wk per 1.73m2 
[complying with the International Society for Peritoneal Dialysis guidelines on PD adequacy 
(21)], 43.6% of them had hyperphosphatemia, which might be amenable by adjusting PD 
prescription to peritoneal membrane phosphate transport rate, since 80% of them were 
slow/slow-average phosphate transporters, 50% of whom were on APD. 
Smaller studies later published (150, 151), reproduced our conclusions. 
Our clinical investigation did not assessed particularities of dialysis prescription, as the 
effects of tidal regimens, dwell times or number of cycles. Phosphate binding prescription was 
also not included, however the lack of correlation between indirect protein intake (nPNA) with 
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serum phosphate levels, the universal uncertainty about phosphate binder accomplishment, 
and the fact that we focused on peritoneal phosphate elimination minimizes this limitation. 
 
Nutrition and body composition in contemporary peritoneal dialysis patients: 
clinical relevant associations  
Protein-energy wasting is common among end stage renal disease patients (81, 82), 
and is an important predictor of mortality in this population (12, 83). The first studies that 
compared nutritional status in patients under different dialysis modalities concluded that 
protein-energy wasting was more prevalent in PD patients, based mostly on albumin serum 
levels and BMI (84). Although a predictor of all-cause mortality in patients under dialysis, 
hypoalbuminemia itself does not necessarily indicate protein wasting, as several other non-
nutritional factors may contribute to lower serum albumin levels in chronic kidney disease 
patients (152-155). It is known that PD patients can lose 6 to 8 grams/day of protein, primarily 
albumin, through the peritoneal membrane. However, there is insufficient evidence that these 
peritoneal protein loses contribute to protein-energy wasting, and the evidence is inconsistent 
about their association with cardiovascular events or all-cause mortality (156). In line with this 
view, an observational cohort study of dialysis patients, undertaken to determine the survival 
predictability of serum albumin level in peritoneal dialysis and hemodialysis patients, 
concluded that serum albumin predicts all-cause, cardiovascular and infection-related 
mortality, both in PD and HD patients, but the threshold at which the risk of death increases 
varies by dialysis modality, being 0.2 to 0.3 g/L lower in PD patients, than for patients 
undergoing maintenance hemodialysis (85). 
According to the most recent diagnostic criteria for protein-energy wasting in CKD 
patients (81), we performed a cross sectional study in order to evaluate nutritional status and 
the prevalence of overweight/obesity in a group of 57 PD patients in treatment in our Unit 
(chapter V.III). To evaluate our patient´s nutritional status, we performed subjective global 
assessment (SGA), anthropometric measurements, and we applied a nutrition status score 
based on serum chemistry (albumin and total lymphocyte count), body mass (BMI, percentage 
of ideal body weight, triceps and subscapular skinfold thickness and subjective physical 
examination) and muscle mass (mid-arm muscle circumference and subjective physical 
examination). By SGA, 70.2% of our patients were classified has having a normal nutritional 
status, and none had severe protein-energy wasting. According to the nutrition status score 
(NSS) applied, only 7% of the patients were mildly-to-moderately malnourished. The results 
obtained with SGA and NSS were corroborated by anthropometric measurements (compared 
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to an age and gender matched population), since 77.2% of our patients had a triceps skinfold 
thickness higher than the percentile 15th, and a similar result was obtained for mid-arm muscle 
circumference (80.7%). Our results were somehow latter corroborated by a recent published 
study that evaluated the body composition of a large number of patients under dialysis (88). 
That study evidenced that patients under PD maintained a better nutritional status in terms of 
lean body mass than their matched paired HD patients, who presented significant lower values 
of body cell mass and lean tissue index, measured by bioimpedance analysis (88). Contrary 
with the first studies on nutritional status assessment in patients under peritoneal dialysis (84), 
our clinical investigation has evidenced that PD patients seem to be relatively protect from 
catabolism as malnutrition is not, nowadays, a common situation in patient under PD (chapter 
V.III).  
According to BMI, 43.9% of the patients evaluated (chapter V.III) were overweight (BMI 
≥ 25Kg/m2) and 7% were obese (BMI ≥ 30Kg/m2). We found no association between 
overweight/obesity and demographic or modality related factors, neither with fast transport 
status. We also found no differences in C-reactive protein, between patients classified as 
overweight/obese and normal-weight patients, although we found significant higher serum 
homocysteine, higher triglycerides and higher total cholesterol/HDL cholesterol ratio in 
overweight/obese patients. As we, other authors (35, 36) documented a high prevalence of 
obesity in PD patients, which reinforce the results that we obtained in this clinical investigation. 
Low BMI is recognized to be strongly associated with worse outcome in HD patients, because 
it reflects a poor nutrition status, in a relation known by reverse epidemiology. In PD field, there 
are contradictory results about the impact of obesity in patient´s outcomes (54, 157, 158). The 
potential atherogenic profile that we documented in the overweight/obese group allows us to 
hypothesize that, as in general population, obesity may be a potential risk factor for 
cardiovascular disease in PD patients. This hypothesis led us to perform a second 
investigation, in order to understand the association between nutritional status and 
cardiovascular disease in patients under PD (chapter V.IV.I). 
In a second clinical investigation, performed in a different PD cohort (chapter V.IV.I), 
we reproduce our previous observation that overweight is widely prevalent in PD patients, 
since 40.9% of the studied patients were overweight and 10.6% were obese. Being a simple 
and accessible tool to characterize obesity, it is recognize that BMI does not differentiate lean 
mass, fat mass and extracellular water. As it is known that PD patients (while maintaining BMI) 
can present simultaneous changes is nutritional status, body fat content and hydration status 
(159), that differently impact on outcome, we wanted to improve our knowledge on this field. 
For that reason, we performed additionally a full body composition assessment of our patients, 
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using multifrequency bioimpedance (BCM, Fresenius Medical Care, Bad Homburg, Germany). 
According to the percentage of relative fat mass assessed by bioimpedance analysis, women 
were classified as obese it they presented a relative fat mass above 30%, and men were 
classified as obese if their relative fat mass was superior to 25% (56). The results obtained 
have clearly demonstrated that our real obesity prevalence was even higher than when we 
used BMI classification, as 73.4% of our patients had a relative fat mass above the previously 
mentioned cut-offs. Using a clinically applicable “bedside” validated method to characterize 
relative fat mass, we were able to demonstrate that BMI clearly underestimates obesity 
prevalence in PD patients. Our results corroborate a clinical investigation that documented that 
a BMI < 30 Kg/m2 does not exclude the presence of obesity, in a group of incident and prevalent 
patients under hemodialysis, evaluated by anthropometry (57). In a third clinical investigation 
performed to assess insulin resistance, in a group of 51 non-diabetic patients currently 
receiving treatment in our Unit (chapter V.IV.II), we obtained similar results concerning obesity 
evaluation, since 33% of the studied patients were considered overweight and 6% were obese 
according to the BMI, but according to bioimpedance analysis, the prevalence of obesity was 
much higher, being 49%, according to the previously mentioned cut-offs of relative fat mass. 
It is important to emphasize that, the bioimpedance method applied (Body Composition 
Monitor – Fresenius Medical care, Bad Homburg Germany), was validated by isotope dilution 
methods (124), by accepted reference body composition methods (127) and by extensive 
clinical assessment of the hydration state (126). We performed bioimpedance analysis in the 
morning of the PET, and we only considered valid measurements that simultaneously 
presented high quality (>90%) and lower error percentage (<35%), showing, in the device 
monitor, an inverted U curve. Currently, there is some debate about the patient´s conditions in 
time of measurement of body composition by bioimpedance, namely whether the presence of 
intraperitoneal effluent could interfere with the results obtained. Based on a critical review of 
the most recent literature, we believe that the presence or absence of PD fluid in the abdomen 
does not influence the readings of hydration status or nutrition parameters. The reason for that 
assumption is based on the fact that due to bio-physical reasons, bioimpedance spectroscopy 
does not measure sequestered fluid in the trunk (127, 160). The issue about differences in 
hydration status due to the presence of PD fluid in the abdomen was specifically addressed by 
two recent studies (161, 162). Both studies evidenced that the difference in fluid overload and 
extracellular water/total body water ratio measured was negligible, neither statistically nor 
clinical significant, when the measurements were performed first in patients with 2 liters of 
glucose solution in the peritoneum, and then after the solution was drained. It is also important 
to emphasize that no study using the body composition monitor device has ever showed any 
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difference in lean body mass, in body cell mass or fat mass readings, according to the 
presence or absence of peritoneal dialysis solution in the abdomen. In fact, in a recent clinical 
investigation, Arroyo D. et al. (128), clearly demonstrated that intracellular water, lean tissue 
mass, lean tissue index, fat tissue mass, fat tissue index, body cell mass and adipose tissue 
mass remained unaffected by abdominal content. 
Glucose remains the most common osmotic agent used in PD solutions because of its 
low price, proved efficiency and easy metabolism. However, there is the fear that with time on 
PD, peritoneal glucose absorption would lead to obesity, dyslipidemia and insulin resistance 
aggravation (34). In line with this view, fast transporters could be even more problematic, since 
they present a more rapidly absorption of the glucose present in the dialysis solutions (163). 
We have carefully explored the possible associations between daily peritoneal glucose 
absorption and small solute transport status with obesity, in two different clinical investigations 
(chapters V.IV.I and V.IV.II). The results obtained were similar and clearly demonstrated the 
lack of association between peritoneal glucose absorption and obesity, and are corroborated 
by two other contemporaneous clinical investigations (36, 164). We also did not found any 
association between fast transport status and obesity, in none of our clinical researches 
(chapters V.III, V.IV.I and V.IV.II), meaning that fast transporters can be adequately managed 
in PD without becoming obese, by using an individualized prescription that matches the 
patient´s peritoneal membrane characteristics. 
 
Nutritional status and adipokines in peritoneal dialysis patients: relationship 
with cardiovascular events   
Cardiovascular disease is the leading cause of death in peritoneal dialysis patients 
(165, 166), and its association with nutritional status has not been sufficiently investigated and 
clarified. Protein-energy wasting, inflammation and atherosclerosis are closely linked in chronic 
kidney disease patients, in an association known by malnutrition-inflammation-atherosclerosis 
(MIA) syndrome (82). Patients with MIA syndrome are more prone to suffer from cardiovascular 
events than patients with a normal nutrition status (83). For another hand, the associations 
between obesity and cardiovascular events are well characterized in general population, but 
remain largely unexplored in CKD patients under PD. With the aim of clarifying the associations 
between cardiovascular events and body composition and adipokines profile in PD, we 
conducted a prospective study including 66 prevalent patients of our Unit, followed for 
47.0±28.2 months (chapter V.IV.I).  
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Our study (chapter V.IV.I) brings some light into the conflicting results about the impact 
of nutritional status in PD patient´s outcomes, concerning new cardiovascular events. As we 
mentioned before, we registered an elevated prevalence of obesity in the studied population 
(73.4%), in line with our (chapter V.III), and others (36) previous researches, and a relatively 
low prevalence of protein-wasting (36%). Patients who presented a cardiovascular event, 
during the follow-up period, were older and had a higher relative over-hydration percentage, 
compared with patients that were free of events, which was expected (167). Concerning body 
composition assessment, there were no differences in lean tissue index and body cell mass 
between patients with and without cardiovascular events, and the percentage of patients with 
protein-wasting classified by bioimpedance analysis was similar between the two groups 
(43.8% vs 35.4%, P=0.565). Contrary to the results obtained concerning lean body mass, fat 
tissue index was slightly higher among patients with cardiovascular events, and the percentage 
of obese patients according to relative fat mass was also significantly higher in this group 
(93.8% versus 66.7%, P=0.029). 
Knowing, from our previous studies (chapter V.III), that obesity is widely prevalent in 
contemporaneous PD populations, we hypothesized that adipokines could be useful markers 
to predict cardiovascular events in these patients. Adipose tissue is now considered an active 
endocrine organ, and numerous adipokines have been implicated in the pathogenesis of 
chronic inflammation and insulin resistance associated with obesity. In vitro and animal studies 
evidenced that leptin has different atherogenic properties, and that adiponectin is an insulin-
sensitizing, anti-inflammatory and anti-atherogenic adipokine (40, 41). Few studies performed 
on CKD patients have addressed the adipokines impact on outcome, with conflicting results 
(74-77, 168) and, until know, only two have specifically studied PD patients (70, 78). However, 
none of the mentioned studies considered the nutritional and hydration status of the patients, 
which could explain the contradictory results obtained, since besides the well-known 
association between adipokines and fat mass (40), high adiponectin and low leptin can both 
reflect wasting, and overhydration can alter the normal regulation of adiponectin (72, 73). 
One of the most important results of our clinical investigation was to document that 
patients who presented cardiovascular events were mostly obese and had also a significant 
higher leptin/adiponectin ratio. However, contrary to Park et al. (70), we were only able to 
document such result on adipokines ratio, once we exclude from the analysis patients with 
protein-wasting. Our study also puts on evidence the fact that protein-wasting is a confounding 
variable that affects adipokines production, since we were able to demonstrate that both 
relative fat mass and lean tissue index were independent predictors of leptin/adiponectin ratio, 
after adjusting for peritoneal glucose absorption. Our results demonstrate that obesity 
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associates with higher leptin levels and lower adiponectin levels that will translate into a higher 
leptin/adiponectin ratio. The opposite situation of protein-wasting is characterized by a lower 
leptin value and a higher adiponectin value that will translate into a lower leptin/adiponectin 
ratio. Given the clear biologic evidence that leptin and adiponectin have opposite effects on 
cardiovascular system, we may hypothesized that in PD patients without protein-wasting, a 
higher leptin/adiponectin ratio is a predictor of cardiovascular events, being an atherogenic 
index in this population. 
We have also explored the potential role of peritoneal glucose absorption and 
peritoneal membrane small solute transport status on obesity (has mentioned before), and on 
cardiovascular events.  Although appealing, once more, we could not find any association 
between peritoneal glucose absorption and fast transport status with obesity, which 
reproduces our previous observation (chapter V.III). Concerning cardiovascular events, we 
were also not able to document any association with peritoneal glucose absorption or with 
membrane transport characteristics. Concerning peritoneal glucose exposure, a recently 
published study concludes that high glucose concentrations in peritoneal dialysate are 
associated with all-cause and cardiovascular mortality, in a group of patients under continuous 
ambulatory peritoneal dialysis (169). However, the authors could not assess if the association 
found with cardiovascular mortality is explained by the potential deleterious systemic effects 
of glucose itself, or by the clinical situation underlining the necessity to use more hypertonic 
glucose. In fact, the authors hypothesized that the association found is explained by the fact 
that peritoneal glucose potentially leads to metabolic syndrome development that will translate 
into a higher cardiovascular mortality. However, the nutritional status of the population studied 
was not evaluated, body composition was not assessed, effective peritoneal glucose 
absorption was not measured, and they gave no information about the prevalence of metabolic 
syndrome in their population. They have performed an analysis on the independent risk factors 
associated with the use of higher dialysate glucose concentrations. They found that older 
patients, with lower residual renal function and with a higher small solute transport rate were 
more likely to require a high glucose load in terms of PD prescription. It is known that older 
patients (170), with RRF loss (171) and fast transporters under CAPD (172) can be prone to 
overhydration, which is a well-known condition that predicts higher cardiovascular mortality in 
patients under dialysis (167). In line with this view, the association found between high glucose 
in the dialysate and cardiovascular mortality could be explained through overhydration, instead 
of being a direct consequence of the potential deleterious systemic effects of glucose, that 
were not effectively measured in this study. 
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There is uncertainty about the clinical outcomes of fast transporters in peritoneal 
dialysis. Although the last meta-analysis published has demonstrated that a higher peritoneal 
membrane solute transport rate is associated with a higher mortality (29), other recent studies 
concluded that the use of continuous cycling peritoneal dialysis seems to offset some of this 
negative effect on mortality (27, 28, 173, 174). In line with this view, we were not able to find 
any association between fast transport status and higher cardiovascular events. Our policy to 
treat fast transporters mostly using APD, with short dwells and using icodextrin for the long 
dwell, may explain the similar clinical outcomes of our patients, independently of their 
peritoneal membrane small solute transport characteristics.  
 
Insulin resistance in non-diabetic peritoneal dialysis patients: associations with 
body composition but not with peritoneal glucose absorption or peritoneal membrane 
fast transport status 
With time on PD, obesity and insulin resistance aggravation are two feared systemic 
consequences of peritoneal glucose absorption, especially in patients who present a peritoneal 
membrane fast transport status. The associations of insulin resistance with clinical outcomes 
in PD were recently investigated (65, 175), but these two studies presented contradictory 
results. Besides, none of these studies has clarified the impact of body composition, nutritional 
status or other factors related with PD prescription, on insulin resistance development, which 
is a meaningful clinical question, since without these relevant information doctors cannot 
develop a successful strategy in order to ameliorate insulin resistance in their patients. Another 
relevant clinical issue, not sufficiently clarified, is the impact of peritoneal membrane fast 
transport status and glucose absorption on insulin resistance. 
The results of our clinical investigation (chapter V.IV.II), evidenced that insulin 
resistance is prevalent even in non-diabetic patients on peritoneal dialysis. It also brings some 
light into the factors responsible for insulin resistance in patients under peritoneal dialysis, 
enhancing the role of obesity and adipokines in this population, as fat tissue index and 
leptin/adiponectin ratio were significant predictors of insulin resistance, measured by 
homeostasis model assessment method (HOMA-IR), independently of peritoneal glucose 
absorption and  peritoneal small solute transport status. 
For the first time in PD field, we documented a significant positive association between 
HOMA-IR and two other adipokines-based insulin resistance indices (HOMA corrected by 
adiponectin and leptin/adiponectin ratio), reproducing the results obtained by Hung et al. (64), 
in patients under chronic hemodialysis. 
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The associations between obesity and insulin resistance in our population were 
documented in several ways. First, insulin resistance indices were strongly correlated with 
body composition parameters related with fat mass (as fat tissue index and relative fat mass), 
but not with parameters related with lean mass (as lean tissue index and body cell mass). 
Second, when patients were categorized as obese and non-obese according to relative fat 
mass measured by bioimpedance, HOMA-IR, HOMA corrected by adiponectin (HOMA-AD) 
and leptin/adiponectin ratio were significantly higher in obese group. The fact that these 
differences were not noticeable when patients were compared concerning BMI, gives an 
indirect evidence that BMI is not an accurate tool to classify obesity in PD patients, which 
reinforces the findings of our previous clinical investigation (chapter V.IV.I). Third, when we 
compared patients according to insulin resistance state (patients with HOMA-IR equal or 
superior to 2.2 and inferior to 2.2), we found that insulin resistant patients had significant higher 
values of relative fat mass and fat tissue index, while maintaining similar values of BMI and 
lean tissue index. Obesity, according to relative fat mass, was also more prevalent in insulin 
resistant patients than in patients with HOMA-IR < 2.2 (84.6% versus 47.8%, P=0.039), while 
the prevalence of wasting was similar between the two groups (38.5% versus 13%, P=0.107). 
Lastly, fat tissue index was an independent predictor of HOMA-IR in the studied patients. 
We might be questioned about the fact that we have measured total body fat mass 
instead of visceral fat mass, a traditional insulin resistance predictor in general population (176, 
177). However, the role of body fat distribution and the metabolic complications of obesity in 
general population has been recently a matter of debate and controversy (178), since there 
are also studies that documented a more important role of upper body subcutaneous fat mass 
on insulin resistance development (179). This may explain the results obtained in a previous 
clinical investigation about insulin resistance predictors in hemodialysis patients (64). 
According to Hung et al. study (64), truncal fat mass and total fat mass, assessed by DEXA, 
were both independent predictors of insulin resistance in a population of 10 patients under 
hemodialysis.  We were not able to perform DEXA or abdominal CT scan on our patients, due 
to financial constraints. We alternatively measured serum IGFBP-1, a recently validated 
surrogate marker of visceral fat, strongly inversely related with liver fat content measured by 
the gold standard method - proton magnetic resonance spectroscopy (180). Our results 
evidence that IGFBP-1 has a strong and negative correlation with HOMA-IR, HOMA-AD and 
leptin/adiponectin ratio, and that serum IGFBP-1 is significantly lower in insulin resistant 
patients (with HOMA-IR equal or superior to 2.2).  
Another clinical relevant result, that deserves to be discussed, is the relationship 
between insulin resistance and the adipokines ratio (LAR) that depends on body composition 
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parameters. We have previously reported that relative fat mass and lean tissue index predicted 
LAR independently of peritoneal glucose absorption (chapter V.IV.I). The results of the 
present study (chapter V.IV.II) corroborate this evidence, underlining further that insulin 
resistance is aggravated in both the extremes of the nutritional spectrum, while LAR present a 
diverse link with HOMA-IR according to such status : 1) protein-energy wasting patients 
evidenced a LAR inferior to 1, and in these patients the correlation between LAR and HOMA-
IR was negative, meaning that as the severity of protein-wasting increases, LAR decreases 
and HOMA-IR increases; 2) in the opposite situation, obese patients exhibited higher LAR 
values, and LAR presented a strong positive correlation with HOMA-IR. Leptin and adiponectin 
play important and opposite roles in the regulation of cardiovascular and metabolic 
homeostasis. In a previous clinical investigation (chapter V.IV.I) we reported that LAR could 
be used as a new atherogenic index, as it was associated with cardiovascular events in PD 
patients without protein-wasting. According to the results now obtained, we may hypothesize 
that the association between LAR and cardiovascular events, that we have previously 
documented, can be explained through insulin resistance development. In fact, given the direct 
actions of adiponectin on insulin sensitivity, both in skeletal muscle and liver (40, 41), a higher 
leptin/adiponectin ratio can been seen not only as a biomarker of insulin resistance but also as 
a predictor of insulin resistance, as our most recent results demonstrate (chapter V.IV.II). 
In this clinical investigation (chapter V.IV.II), peritoneal glucose absorption showed no 
association with obesity profile, which reproduces our previous results (chapter V.IV.I) and 
others author´s observations (36, 164). We are aware that the glycemic and insulinemic 
responses differ after a similar oral glucose dose and intra-peritoneal glucose administrations. 
The cephalic phase of insulin release, and specially the enteric release of cholecystokinin, 
gastric inhibitory polypeptide and glucagon-like peptide 1 (GLP-1), which are bypassed during 
the peritoneal administration of glucose, explain the more physiological insulinemic response 
that is seen after oral glucose administration, compared with the intra-peritoneal route. This 
incretin effect partially explains the greater rate of glucose disappearance from plasma, and 
the greater rate of cellular utilization of glucose that is observed in the first 180 minutes after 
an equivalent oral glucose load compared with the intra-peritoneal administration. However, 
although peritoneal glucose administration is not as physiological as the oral route, we still 
were not able to document any association between peritoneal glucose absorption and insulin 
resistance in our patients. As we already mentioned, one of the most feared systemic 
consequences of glucose absorption in PD is precisely obesity and insulin resistance 
development. The fact that we didn´t found any association between peritoneal glucose 
absorption and insulin resistance indices, doesn´t mean that glucose is not an important 
variable in the complex situation of obesity and insulin resistance development in PD. More 
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than that, our results reinforce that with contemporary therapies, that avoid excessive glucose 
exposition, absorbed glucose is not associated with insulin resistance, but adiposity is. 
Therefore, our findings put on evidence that other variables such as dietary intake, energy 
expenditure, and genetics (that partially determines resting energy expenditure) might be more 
powerful determinants of obesity, deserving focused investigation.  
 Given the fact that fast transporters have been previously associated with a gloomy 
outcome (26, 29), we specifically studied this group concerning cardiovascular events and 
insulin resistance (chapters V.IV.I and V.IV.II), testing whether fast transporters are prone to 
obesity and insulin resistance development (34). The results that we obtained with two different 
clinical investigations cannot support such a chain of events (chapters V.IV.I and V.IV.II).  
First, none of our studies documented any association between peritoneal small solute 
transport status and obesity profile (chapters V.III, V.IV.I and V.IV.II). Second, we could not 
find any association between peritoneal small solute transport status and cardiovascular 
events, in a group of 57 PD patients followed for 47 months (chapter V.IV.I). Third, in a study 
about insulin resistance prevalence in a group on 51 non-diabetic PD patients, we also did not 
find any significant difference concerning leptin/adiponectin ratio, IGFBP-1, HOMA-IR, HOMA-
AD, peritoneal glucose absorption, neither in body composition parameters related with fat 
mass, between fast transporters and the other small solute transport categories (chapter 
V.IV.II). To our knowledge, only two studies evaluated the associations between peritoneal 
small solute transport and insulin resistance measured by HOMA-IR (181, 182), and both 
evidenced a lack of correlation between D/P creatinine and HOMA-IR. Our results not only 
support such evidence, but further expands the knowledge about fast transport status systemic 
consequences, highlighting that fast transporters under updated therapy regimens have no 
higher risk for obesity and insulin resistance development. 
 Systemic inflammation was recently documented to be an independent predictor of 
survival in PD (90), but the factors that may trigger inflammation were not sufficiently clarified. 
As others (183), we found an association between inflammation and obesity. However, we 
were just able to document such association, when patients were characterized according to 
relative fat mass by bioimpedance analysis, but not when patients were classified according 
to BMI. Indeed our studies evidenced that IL-6 (chapter V.IV.I) and C-reactive protein (chapter 
V.IV.II) were significantly higher in obese patients, classified according to relative fat mass 
percentage. Concerning insulin resistance evaluation (chapter V.IV.II), we also found that 
patients with HOMA-IR superior or equal to 2.2 presented higher C-reactive protein levels, 
although the difference was not statistically significant. The small number of patients evaluated 
could preclude us from obtaining a significant result. Besides, there are other inflammatory 
cytokines known to be more related with insulin resistant states, such as TNF-alfa, IL-1 and 
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IL-6 (40), that were not measured. As Lambie M. et al. (90), we also did not found any 
association between systemic inflammation and small solute transport status. However, 
contrary to that study, we could not find any association between fatal and non-fatal 
cardiovascular events and a fast transport status (chapter V.IV.I). We hypothesized, once 
more, that our PD prescription policy can explain our patient´s better outcome, since contrary 
to the Global Fluid Study, the majority of our fast transporters are prescribed with APD and 
icodextrin. In fact, our results are supported by others recent clinical investigations that 
evidence that a peritoneal membrane fast transport status is no longer associated with worse 
outcome, in cohorts using APD and icodextrin (27, 173, 174). The axis of pathophysiology 
between fast transport and reported worse outcomes is probably much more related with 
volume control and hypervolemia driven systemic inflammation, than merely related with 
glucose absorption. On the other hand, glucose and its glucose degradation products are 
promoters of membrane functional loss (34). Therefore, even if there is no evidence of a strong 
link between peritoneal glucose exposition and insulin resistance or obesity development, still 
glucose sparing regimens are recommendable to minimize membrane loss, hypervolemia risk 
and associated mortality. 
Finally, some formal methodological issues deserves further discussion, namely the 
HOMA-IR cut-off chosen to classify patients for insulin resistance, the importance of insulin 
analytical determination, and the potential effects of peritoneal glucose concentration on serum 
insulin and glucose measurements. 
Concerning the HOMA-IR cut off, patients with HOMA-IR ≥ 2.2 were considered to 
present insulin resistance, as this value corresponds to HOMA-IR percentile 50 in the larger 
validation study about HOMA-IR against the euglycemic, hyperinsulinemic clamp in non-
diabetic patients (60).  
It is also important to stress that insulin assays can vary considerably, especially if 
antibodies cross-reacting with insulin or split-proinsulin products are used (184).We have 
minimize any potential interference exerted on HOMA-IR score, by using an insulin-specific 
assay. 
We calculated insulin resistance (HOMA-IR) by measuring fasting plasma glucose and 
fasting plasma insulin after an overnight fast (8 to 10 hours fast), but with continuation of PD 
therapy in a standardized way, with 1.36% glucose in the last dwell. We considered that this 
standardization concerning the last dwell adds accuracy to our methodology and is a strength, 
since the majority of studies that calculate HOMA-IR in PD patients lack in standardization of 
PD prescription, with maintenance of the usual prescription (65, 175, 181). We have carefully 
chosen to performed the last dwell with the lowest concentration of glucose in the dialysate 
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(1.36% glucose), based on the measured effects on plasma glucose and plasma insulin of a 
single 6-hour dialysis cycle with 1.36% glucose solution, that was previously investigated, in a 
group of non-diabetic patients on continuous ambulatory peritoneal dialysis (31). The 
investigation performed by Heaton A. et al. (31), clearly showed that plasma insulin was not 
significant different, in any moment, along the 360 minutes study, between patients without 
glucose in the abdomen compared with patients with 2 liters of 1.36% glucose solution. 
Concerning plasma glucose, the difference between undialysed patients and patients with 
1.36% glucose solution in the abdomen, was only significant at 45 minutes, and the results 
were not different between 60 and 360 minutes. The results expressed by Heaton A. et al. 
(31), enabled us to perform a protocol to investigate the presence of insulin resistance in our 
PD population, measuring plasma glucose and insulin in a fasting state, minimizing any 
interference from peritoneal glucose. In patients under CAPD, the last dwell was performed at 
23 h and the blood was collected at 9 am after the drainage of the peritoneal cavity and before 
the PET starts. In patients under APD, we also changed the prescription and told our patients 
to use 1.36% glucose has their last exchange. In patients under APD, the blood was also 
collected after drainage of the peritoneal cavity, before the PET starts, and we have ensured 
that the previous dwell was performed with 1.36% glucose solution. As the previously cited 
investigation (31) showed that there are no differences in plasma glucose and insulin between 
undialysed PD patients and patients with 1.36% glucose solution, after the first 60 minutes of 
a dwell, we think that our protocol minimizes any potential effect of peritoneal glucose 
absorption, while it allows the patients to maintain dialysis.   
 
Peritoneal membrane functional evaluation: free water transport quantification 
and the potential value of effluent hepatocyte growth factor to timely characterize 
peritoneal membrane dysfunction 
Over time, peritoneal dialysis results in structural alterations of the peritoneal 
membrane (96), hardly assessed in clinical practice. These structural alterations will promote 
membrane functional changes that are worth to be evaluated through peritoneal equilibrations 
tests, as they have therapeutic implications in terms of dialysis prescription (185). Although 
there are several peritoneal equilibration tests available for routine clinical practice, the type of 
information provided by each of them is different, and for that reason, each clinician should 
elect the PET that provides the most useful information in terms of peritoneal membrane 
functional characterization (185). We report (chapter V.V.I), simultaneous small-pore and 
ultrasmall-pore peritoneal transport quantification, through the use of a 4-hour 3.86% glucose 
PET with temporary drainage at 60 minutes, expanding a previous report from Cnossen et al. 
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(110). Our clinical investigation also expands the work of La Milia group (106), because our 
Two-in-One Protocol allows peritoneal ultrafiltration measurement at 1 hour [as the mini-PET 
(106)], while it maintains a total duration of 4 hours [as a standardized, or modified PET (104)]. 
This protocol enabled us to simultaneously quantify ultrafiltration through ultrasmall pores and, 
at the same time, characterize the membrane according to small solute transport, as in a 
standardized PET, without occurring the overestimation that might happen when small-solute 
transport categorization is based on a D/Pcreatinine obtained after a 1 hour dwell (109). 
The results that we have obtained, in terms of FWT and FWT percentage, were in line 
with those obtained with a standard permeability test (107), a more sophisticated method 
hardly used in daily clinical practice. Also, skilled studies from Waniewski J. et al. (186, 187), 
found a FWT fraction of 0.40±0.12, which is equivalent to the FWT percentage that we 
obtained. 
The fact that FWT correlated better with total ultrafiltration than with any indirect 
measure of sodium sieving was already expected, given the fact that a reduced water flow 
through the aquaporins is not the only plausible cause that determines a sodium sieving 
reduction (188). 
We have performed a correction for sodium diffusion using the mass transfer area 
coefficient for creatinine (MTAC Creatinine), calculated by the simplified Garred model (189). The 
same methodology was also followed by other groups that have investigated peritoneal fluid 
pathways (190, 191) and exhibits good correlation with the Waniewski model (109). We also 
have performed a FWT correction for lymphatic absorption and for the ultrafiltration through 
the large pores, during the first 60 minutes of the dwell, according to an algorithm validated by 
computer simulation model (108).   
We documented a slight, but consistent, tendency for total ultrafiltration and FWT 
decline with time on PD. Patients with ultrafiltration failure evidenced a FWT significantly lower 
and a D/Pcreatinine significantly higher, when compared with patients without ultrafiltration failure. 
However, FWT fraction was similar between the two groups, which is line with Parikova et al. 
(100), that has demonstrated that in the first years of PD treatment, an increase of vascular 
peritoneal surface area will lead to a rapid disappearance of the osmotic gradient and thereby 
promote some reduction in FWT, but not in its contribution to total ultrafiltration. 
Another relevant aspect of our clinical investigation, that deserves to be discussed, is 
the opposite correlation that we found between small-pore and aquaporin water transport in 
patients with and without ultrafiltration failure. In fact, we have documented a positive 
correlation between small-pore and free water transport in patients without ultrafiltration failure 
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(r=0.257, p=0.032), in line with the fact that, in a non-pathological setting, FWT depends on 
osmotic gradient and effective capillary surface (188). However, in patients with acquired 
ultrafiltration failure, a negative and more powerful correlation was documented between small-
pore and free water transport pathways (r=-0.709, p=0.015). In order to explain this opposite 
profile found in ultrafiltration failure situation, we have hypothesized that some of our patients 
with most severe forms of ultrafiltration failure could present an interstitial fibrosis process that 
would explain this “uncoupling” between changes in small-pore transport and in FWT. He have 
formulated this hypothesis based on a previous investigation about simulations of osmotic 
ultrafiltration failure in CAPD, using a serial three-pore membrane/fiber matrix computational 
model (192). According to that study, an uncoupling of small solute transport from ultrafiltration 
coefficient (LpS) was documented in computer simulations of ultrafiltration failure, whenever 
changes in both vasculature and in interstitium were taken into account. In fact, when the 
authors investigated the impact of increasing the effective vascular surface area (S) 
concomitantly with altering the fiber composition and by adding (collagen) fibers to the 
interstitium, they evidenced a reduction of ultrafiltration capacity of the total capillary-interstitial 
barrier, while only little affecting small solute transport and glucose reflection coefficient 
(sigma). Our results, on functional membrane properties in ultrafiltration failure setting, were 
posteriorly validated and corroborated by a recent clinical research, that has analysed 
peritoneal membrane samples of patients with encapsulating peritoneal sclerosis (102). This 
study confirms that structural changes in the peritoneum interstitium account for an excessive 
reduction in osmotic conductance without affecting small solute transport, as we have 
previously hypothesized that would occur in our patients with the most severe ultrafiltration 
failure forms that presented, in a functional peritoneal membrane evaluation, a FWT 
compromise beyond of what would be explained by an increase in capillary surface. 
In a clinical point of view, our study has enabled us to identify other important causes 
of ultrafiltration failure, beyond the increase in effective capillary surface, with repercussion in 
the therapeutic managing of these patients. In fact, among the 11 patients with ultrafiltration 
failure, five had a FWT fraction contribution to ultrafiltration at 60 minutes inferior to 45%, but 
only two of them were fast transporters. That finding suggests again a higher compromise of 
FWT, disproportionate to small-solute transport. As a therapeutic strategy, those patients with 
FWT severe compromise will benefit most from icodextrin instead of hypertonic glucose 
prescriptions. Thus, one of the most important clinical implications of using the Two-in-One 
protocol, to our daily clinical practice, is that it allowed us to understand and monitor 
longitudinally the functional characteristics of our patient´s peritoneal membrane, improving 
our capacity to prescribe a dialysis program that matches each patient membrane 
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characteristics and timely detect signs of alarm relative to the risk of encapsulating peritoneal 
sclerosis. 
Several clinical studies, and others based on computational models, have already 
demonstrated that impaired free water transport indicates a more severe functional and 
structural lesion of the peritoneal membrane, due to aquaporin dysfunction or interstitial 
changes (100, 105, 193-195). In fact, a recent clinical research has documented that patients 
with encapsulating peritoneal sclerosis (EPS) presented early loss of ultrafiltration capacity 
and sodium sieving 2 years before the onset of EPS, compared with long-term PD controls 
(102). In a multivariate analysis, sodium sieving was the only independent risk factor 
associated with EPS, outperforming other clinical variables, commonly associated with a 
higher EPS risk, such as age at dialysis onset, PD duration, residual renal function, beta-
blocker use and peritonitis rate. Furthermore, according to the same study, submesothelial 
thickness presented strong negative correlations with net ultrafiltration and with sodium 
sieving, but no correlation was found with small-solute transport evaluated with D/Pcreatinine at a 
4 hours PET. These recently proven functional-structural peritoneal membrane correlations, 
associated with the fact that the performance of serial peritoneal biopsies to detect morphology 
modifications is not feasible in PD patients, makes desirable the search for a biomarker that 
correlates both with ultrafiltration and with free water transport, and not only to the membrane 
small solute transport status. The use of effluent biomarkers as an early sign of peritoneal 
membrane alterations is currently under debate (111-113), and studies provided different 
results. In a recent report (111), monocyte chemotactic protein-1 (MCP-1), interleukin-6 (IL-6) 
and leukotactin (CCL15), were found at higher levels in the peritoneal effluent of patients who 
subsequently developed EPS, although without improving prediction of future EPS risk above 
known clinical factors, such as PD vintage and peritoneal small solute transport status. On the 
contrary, Sampimon et al. (112) evidenced that dialysate appearance rate of IL-6 and CA125 
combined was potentially useful for an early diagnosis of EPS. However, none of these studies 
has explored the associations between the measured cytokines in the effluent and water 
transport pathways, especially with free water transport, given the important functional-
structural correlations that were already mentioned.  
To our knowledge our group was the first to report a clinical significant association 
between hepatocyte growth factor (HGF) measured in the effluent, FWT quantification and 
ultrafiltration profile (chapter V.V.II).  Given the fact that HGF is constitutively synthesized by 
human peritoneal mesothelial cells and it is known to block high glucose induced epithelial-to-
mesenchymal transition, ameliorating peritoneal fibrosis (93), we hypothesized that the 
increased effluent HGF that we found in patients with ultrafiltration failure, especially in patients 
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with the most UFF severe forms (with FWT fraction compromise), could be seen as a reactive 
repairing mechanism, being an early sign of peritoneal membrane deterioration. In fact, our 
study adds further clinical evidence to a previous report that studied focal HGF expression in 
peritoneum biopsies of PD patients with and without ultrafiltration failure (196). According to 
Nakamura et al. (196), there was an increased expression of HGF in peritoneal tissues of 
CAPD patients with low ultrafiltration capacity compared with the group with a normal 
ultrafiltration profile. Once more, these results give strength to our hypothesis that the higher 
HGF concentration that we found in patients with FWT compromise, on top of an increased 
small-solute transport, can been seen as a reactive mechanism to peritoneal membrane lesion. 
The peritoneal effluent HGF concentration was measured, until now, by a single clinical study 
(118). However, Mizuiri S. et al. (118) have only compared effluent HGF concentration 
according to small-solute transport, and gave no information about ultrafiltration failure or water 
transport pathways profile of the population evaluated. Since there are no clinical studies that 
had examined plasma and effluent HGF, and we have also found a correlation with small-
solute transport, we might question whether effluent HGF concentration could depend on 
plasma HGF levels. We think that this is not plausible for various reasons. First, the peritoneal 
permeability is expected to be poor, since HGF is a heterodimeric molecule composed of a 69 
KDa alpha subunit and a 34 KDa beta subunit. Second, we couldn´t find any correlation 
between effluent HGF concentration and small-pore water transport, meaning that HGF is not 
significantly diffusible. Third, Yu et al. (93) demonstrated that human peritoneal cells 
constitutively synthesized HGF, and Nakamura et al. (196) showed that HGF can be expressed 
at the peritoneal membrane level, especially in PD patients with ultrafiltration failure. For these 
reasons, we believe that the HGF protein detected in the effluent is locally produced.   
All patients included in this clinical investigation (chapter V.V.II) performed a peritoneal 
membrane transport functional test using the Two-in-One Protocol (chapter V.V.I), whose 
specifications and advantages were already discussed. The evaluation performed enabled us 
to classify nine patients as having ultrafiltration failure. Three had a more severe profile 
characterized by FWT compromise (FWT ≤45%) and increased effective capillary surface 
(D/Pcreatinine≥0,81). Those patients had significant lower ultrafiltration volume at a 4-hour PET 
(166,7±57,7 mL vs 375,0±41,8mL, p=0,024), lower FWT quantification (128,7±26,5 mL vs 
183,5±12,1 mL, p=0,024) and higher MTACcreatinine (25,4 ± 2,6 mL/min vs 9,6±2,5 
mL/min,p=0.024). Patients with the more severe UFF profile had also higher values of HGF 
measured in the effluent (104,3 pg/mL vs 88,9 pg/mL, p=0.085). Another three patients, 
although not fast transporters, presented an increased effective capillary surface when 
compared with their previous MTACcreatinine result (on a previous PET).The rapid disappearance 
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of the osmotic gradient contributed for UFF in those patients, while FWT was not impaired. 
The last three patients were incident, with few months on PD (3 – 6 months). According to 
small solute transport they were average transporters with no FWT impairment. A high effective 
lymphatic absorption rate could be the reason for UFF in those incident patients, since high 
lymphatic absorption is recognized to be mostly a cause of inherent UFF (193). It is noteworthy 
that mean HGF in those three patients (with a functional UFF) was significantly lower compared 
with the 3 patients that had impaired FWT [77.84 (67.9 – 79.8) pg/mL vs 104.3 (103.7 – 147.16) 
pg/mL, p=0.05]. 
In this clinical investigation we reported a FWT fraction of 45% which is in line with ours 
(chapter V.V.I), and others (106) previous observations. A FWT fraction inferior to 45% is 
clinical relevant in patients with ultrafiltration failure, as it may signalize an aquaporin 
dysfunction or a process of interstitial fibrosis, that will promote a decrease in the membrane 
osmotic conductance to glucose (100). However, there is actually no knowledge about the 
clinical meaning of a FWT reduction in patients without ultrafiltration failure. This is another 
relevant aspect of our investigation: a FWT fraction ≤45% without clinical ultrafiltration failure 
was documented in some patients, who also had increased dialysate HGF concentration 
compared with patients with preserved FWT fraction. We can hypothesized that this may 
represent an intermediate level of peritoneal dysfunction, where the patient may already have 
some interstitial changes that lead to a reactive increase in HGF production, while not severe 
enough to functionally present an ultrafiltration failure. Aging, uremia and diabetes are often 
associated with membrane changes already at PD start, possibly justifying, in some patients, 
selective FWT compromise in absence of a clinically relevant ultrafiltration failure (197-199). 
 One of the limitations of our studies on peritoneal membrane functional evaluation is 
the inability of our Two-in-One protocol to quantify lymphatic absorption rate, which is not 
feasible in daily clinical practice, and whose methodology is still under debate (200). We are 
also aware that assuming a constant rate of 0.3 mL/minute for peritoneal lymphatic absorption 
is a simplification of the three-pore model, as it may differ between patients. Furthermore, we 
were able to identify a higher lymphatic absorption, as a plausible cause of ultrafiltration failure, 
in some of our patients, by exclusion. In fact, peritoneal absorption remains a difficult problem 
to investigators as no clinical procedure, feasible in daily clinical practice, is able to quantify 
lymphatic absorption, except by using  macromolecular tracer such as dextran (201) or 
radioiodinated human serum albumin (202, 203).  
Our studies were also limited by their cross sectional design and small number of 
patients with ultrafiltration failure. A longitudinal study is being conducted in order to better 
understand the clinical meaning of a decreased FWT in patients without ultrafiltration failure, 
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and also to document the dynamic profile of HGF production and its relationship with peritoneal 
membrane water transport changes. 
 
 Future investigations 
Preservation of residual renal function is patients under peritoneal dialysis: the 
role of new PD solutions and beyond 
In the clinical investigation performed (chapter V.I), we concluded that diabetes was 
the only independent predictor of anuria, after PD start. Although more than 50% of the 
population under analyse was treated with PD solutions low in glucose degradation products, 
we were not able to determine the effect of these new solutions concerning residual renal 
function loss. This subject has been recently matter of investigation. In fact, according to a  
recently published meta-analysis about the effect of neutral-pH, low-glucose degradation 
products peritoneal dialysis solutions, on residual renal function, these more biocompatible 
solutions resulted in better preservation of RRF that persisted beyond 12 months (204). 
However, there is still room to investigate whether there is a link between uraemia per se and 
peritoneal structural and functional changes, and if kidney function protection may also be 
independently associated with peritoneal membrane preservation. Additionally, the differential 
qualitative impact of kidney filtration rate versus diuresis in outcomes and systemic 
inflammation certainly merits further investigation. 
 
Obesity determinants in peritoneal dialysis patients: the role of dietary intake, 
genetics and energy expenditure 
 We observed, in a reproducible manner, in two different clinical investigations 
(chapters V.IV.I and V.IV.II), a lack of association between peritoneal glucose absorption and 
obesity development, in patients under peritoneal dialysis. We also concluded that peritoneal 
glucose absorption is not associated with insulin resistance development, in our patients, but 
adiposity is.  
Our studies were limited by their cross-sectional design, and for that reason we aim for 
a longitudinal extension of these investigations. Nevertheless, our findings put on evidence 
that other variables such as dietary intake, energy expenditure, and genetics (that partially 
determines resting energy expenditure) might be more powerful determinants of obesity, 
deserving focused investigation. 
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The gut releases several peptides upon feeding, which affect hypothalamic pathways 
involved in the regulation of satiety and food intake. Cholecystokinin (CCK) and glucagon-like 
peptide-1 (GLP-1) signal to the brain and provide satiety signals. This gut-brain axis regulation 
of glucose metabolism deserves focused investigation in peritoneal dialysis field, as the intra-
peritoneal route bypasses gut hormones and their action on food intake regulation by the 
hypothalamus.  
 As we, Vasselai et al. (36) also found no association between fat mass gain in PD 
patients and peritoneal glucose absorption. In fact, they found that patients who presented fat 
mass gain, after one year under PD, presented a higher ratio of caloric intake/energy 
expenditure, when compared with patients that lost fat mass, while the daily peritoneal glucose 
absorption was similar between the 2 groups. More studies focused on the relation between 
obesity and energy expenditure in PD field are needed. 
 Heritability studies, in the general population, suggest that as much as 70% of the 
variability in human body weight may be accounted for by genetic factors (205, 206). In 
peritoneal dialysis field, studies on obesity genetics are scarce. Nordfors et al. (207), 
documented that patients with the deletion/deletion uncoupling protein 2 genotype presented 
more fat tissue gain during one year in PD, than those patients with the insertion/deletion 
uncoupling protein 2 genotype . More studies under these subject are needed, in order to 
improve our knowledge on obesity pathogenesis in patients under PD, and to enhance our 
ability to treat these patients successfully.  
 
Potential therapeutic options to reduce insulin resistance in patients under 
peritoneal dialysis 
Few studies specifically addressed the potential role of icodextrin-based solutions in 
reducing insulin resistance in patients under peritoneal dialysis (208-212). Although the 
majority of these studies report a lower HOMA-IR value when patients are prescribed icodextrin 
for the long dwell, those results have to be cautiously interpreted. The low number of patients 
included (12 to 34 patients), the short follow-up time (3 to 9 months), but especially some 
methodological constraints related to the non-fasting state of the patients when glucose and 
insulin measurements are taken, preclude a definitive conclusion. In order to clarify the 
potential role of icodextrin in insulin resistance, in patients under PD, more studies are needed 
that strictly comply with the principles of a true fasting state when blood samples are collected, 
with a dialysis prescription protocol that minimizes any potential interference of peritoneal 
glucose solutions. 
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Synthetic activators of PPARƔ, called thiazolidinediones, act as effective insulin 
sensitizers, thereby reducing plasma insulin levels and, theoretically, the complications 
associated with hyperinsulinemia. In patients under peritoneal dialysis, a single study has 
investigated the potential effect of oral pioglitazone on insulin resistance and adipokines 
balance (213). According to Li et al. (213), insulin resistance measured with HOMA-IR has 
significantly declined, and adipokines balance has improved, after a 12 week period of 
treatment with pioglitazone. However, additional prospective studies are warranted to confirm 
these findings, as this study has enrolled only 36 patients, and 28% of them were diabetics (a 
sub-group where the beneficial effects of thiazolidinediones were already expected). 
Since peritoneal glucose administration bypasses the gut and the incretin effect of 
enhancing glucose-dependent insulin secretion, glucagon-like peptide-1 based therapies 
could enhance glucose metabolism in patients under PD. The particular effect of linagliptin, a 
dipeptidyl peptidase 4 inhibitor that is primarily eliminated via enterohepatic system, is thus a 
theoretical potential candidate to ameliorate insulin resistance in patients under PD.  
 
Investigations on free water transport profile with time on PD and the dynamic 
profile of HGF production 
Our studies on peritoneal membrane function evaluation were limited by their cross 
sectional design and small number of patients with ultrafiltration failure (chapters V.V.I and 
V.V.II). Therefore, a longitudinal study is being conducted in order to better understand the 
clinical meaning of a decreased FWT in patients without ultrafiltration failure, and also to 
document the dynamic profile of HGF production and its relationship with peritoneal membrane 
water transport changes. 
 
Investigations on pharmacological agonists of the aquaporins 
 The identification of the ultra-small pores offers the opportunity to modulate water 
transport in PD. Studies in rat and mouse models (214, 215), and in patients under PD (216), 
have shown that an aquaporin-1 modulation can be achieved without modifying the osmotic 
gradient. Whether increasing the expression of aquaporin-1 in the membrane, or gating the 
already existing channels, could be used to treat patients with ultrafiltration failure, remains to 
be investigated. 
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V I I .  CONCLUSIONS  
Predictors of residual renal function loss in PD patients 
Our first clinical investigation (chapter V.I) has evidenced that patients on PD after 
renal transplantation experience similar short term residual renal function protection, without a 
shorter peritonitis-free survival, compared with patients starting PD, as their first renal 
replacement therapy. We also concluded that diabetes was the only independent predictor of 
anuria after PD start. 
 
Peritoneal membrane phosphate transport status 
Our second clinical investigation (chapter V.II) contributed to increasing our 
understanding on peritoneal phosphate clearance, by highlighting the importance of 
establishing peritoneal membrane phosphate transport status. We concluded that in 
hyperphosphatemic and or anuric patients, the decision on the optimal PD modality should 
also take into account peritoneal phosphate transport characteristics, beyond the traditional 
adequacy parameters (urea Kt/V and creatinine peritoneal clearance). Increasing dwell times 
or transfer to CAPD could be effective strategies to improve phosphate handling in patients 
with inadequate phosphate control on APD, especially if they are slow phosphate transporters. 
 
Evaluation of nutritional status in contemporary PD patients 
According to the most recent diagnostic criteria for nutritional assessment in chronic 
kidney disease patients, we have documented a high overweight and obesity prevalence, and 
a low incidence of protein-wasting in patients under peritoneal dialysis, using several 
biochemical and anthropometric parameters (chapter V.III). These results were reproduced in 
a subsequent study, (chapter V.IV.I), and we further demonstrated that body mass index (BMI) 
underestimates the real prevalence of obesity, compared with body composition assessment 
using bioimpedance analysis (chapter V.IV.I). 
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The impact of peritoneal glucose absorption and fast transport status on obesity, 
insulin resistance and new cardiovascular events in PD patients 
According to our clinical investigation (chapter V.IV.I), cardiovascular events were 
associated with obesity. Furthermore, we could not find any association between obesity and 
peritoneal glucose absorption, neither with fast transport status. This study enabled us, 
additionally, to clarify that adipokines profile depends on patient´s body composition, as 
leptin/adiponectin ratio was predicted by relative fat mass and lean tissue index, independently 
of peritoneal glucose absorption. In line with these results, obese patients presented higher 
leptin and lower adiponectin level that translated into a higher leptin/adiponectin ratio; patients 
with protein-wasting presented a lower leptin and a higher adiponectin that translated into a 
lower leptin/adiponectin ratio. Our results can therefore explain the previously reported 
contradictory results about adiponectin and clinical outcomes, in patients with chronic kidney 
disease. We have also concluded that a higher leptin/adiponectin ratio was associated with 
cardiovascular events, and can represent a new atherogenic index in patients under PD, 
without protein wasting.   
In a subsequent clinical investigation about insulin resistance in non-diabetic PD 
patients (chapter V.IV.II), we concluded that obesity and adipokines profile play a major role 
in insulin resistance development in PD, independently of glucose absorption and small solute 
transport status. In practice, this study puts on evidence that the concept of reversal 
epidemiology that was found in several hemodialysis populations may not be applied to PD 
patients. Given the already established association between insulin resistance, namely 
between higher LAR, and cardiovascular events (as our previous investigation demonstrates 
– chapter V.IV.I), efforts should be put in obesity prevention, correct diagnosis and treatment. 
One of the most feared systemic consequences of glucose absorption in PD is precisely 
obesity and insulin resistance development. However, contemporary PD treatments minimize 
such exposition, and the lack of correlations between peritoneal glucose absorption, insulin 
resistance indices and body composition parameters that we found, puts on evidence that 
other factors (such as genetics, energy expenditure and energy intake) may contribute to a 
metabolic syndrome development in PD patients, perhaps in a more powerful way. Finally, 
with this investigation, we also concluded that fast transporters can be adequately managed 
in PD, without becoming obese or developing an insulin resistant state. Using new solutions, 
with low glucose degradation products, icodextrin and short dwells could contribute to minimize 
glucose exposure, as an updated therapy that could successfully treat fast transporters in 
peritoneal dialysis. 
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Functional characterization of peritoneal membrane 
Our clinical investigation on functional evaluation of the peritoneal membrane (chapter 
V.V.I), allowed us to conclude that quantification of free water transport (FWT) is important for 
detecting causes of ultrafiltration failure (UFF), beyond an increase in effective capillary 
surface, and that such quantification is feasible during a 4-hour, 3.86% glucose PET 
evaluation, with a temporary drainage of the peritoneal cavity at 60 minutes, in a Two-in-One 
PET Protocol. 
In a subsequent clinical investigation (chapter V.V.II), hepatocyte growth factor (HGF) 
was explored as a potential new effluent biomarker that could timely signalize peritoneal 
membrane dysfunction. We concluded that dialysate HGF concentration is significantly higher 
among patients with UFF, especially if FWT is impaired, suggesting that it might be a useful 
marker of progressive peritoneal membrane dysfunction. 
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